Conditions: Healthy
Allocation: NON_RANDOMIZED | Intervention model: CROSSOVER
Enrollment: 16
Healthy volunteers: yes

Brief summary:
The main objective of this trial is to investigate the effect of rifampicin on the pharmacokinetics of BI 894416.

Detailed description:

Arms:
arm 1: Reference (Period 1) followed by Test (Period 2) arm 2: None

Interventions: intervention 1: BI 894416 intervention 2: Rifampicin
Intervention descriptions: intervention 1: tablet intervention 2: tablet

Protocol document:
Prot_000.pdf: 
001-MCS-40-106-RD-13 (6.0) / Saved on: 13 Jun 2018
Clinical Trial Protocol
TITLE PAGE
Document Number:
c26448055-04
EudraCT No.
2019-000507-33
BI Trial No.
1371-0005
BI Investigational
Medicinal Product
BI 894416
Title
Effect of rifampicin on the pharmacokinetics of a single oral dose 
of BI 894416 in healthy male subjects (an open-label, one-way 
crossover study)
Lay Title
A study in healthy men to test whether rifampicin influences the 
amount of BI 894416 in the blood
Clinical Phase
I
Clinical Trial Leader
Phone:
Fax: 
Principal 
Investigator
Phone: 
Fax: 
Status
Final Protocol (Revised Protocol (based on global amendment 3))
Version and Date
Version: 4.0
Date: 09 September 2019
Page 1 of 67
Proprietary confidential information
© 2019 Boehringer Ingelheim International GmbH or one or more of its affiliated companies. All rights reserved.
This document may not - in full or in part - be passed on, reproduced, published or otherwise used without prior written permission


Boehringer Ingelheim
09 Sep 2019
BI Trial No.: 1371-0005
c26448055-04
Trial Protocol
Page 2 of 67
Proprietary confidential information © 2019 Boehringer Ingelheim International GmbH or one or more of its affiliated companies
001-MCS-40-106-RD-13 (6.0) / Saved on: 13 Jun 2018
CLINICAL TRIAL PROTOCOL SYNOPSIS
Company name
Boehringer Ingelheim
Protocol date
11 March 2019
Revision date
09 September 2019
BI trial number
1371-0005
Title of trial
Effect of rifampicin on the pharmacokinetics of a single oral dose of BI 894416 in 
healthy male subjects (an open-label, one-way crossover study)
Principal Investigator:
Trial site
Clinical phase
I
Trial rationale
Based on in vitro data, CYP3A is involved in metabolism of BI 894416. It is 
necessary to explore the effect of CYP3A induction on the pharmacokinetics of 
BI 894416. 
Trial objective
The main objective of this trial is to investigate the effect of rifampicin on the 
pharmacokinetics of BI 894416.  
Trial design
Open-label, one-way crossover design
Trial endpoints:
Primary endpoints: AUC0-and Cmax of BI 894416
Secondary endpoint: AUC0-tz of BI 894416
Number of subjects 
total entered
16
each treatment
16
Diagnosis
Not applicable
Main criteria
for inclusion
Healthy male subjects, age of 18 to 50 years (inclusive), body mass index (BMI) of 
18.5 to 29.9 kg/m2 (inclusive)
Test product 1
BI 894416 tablet (strength: 25 mg)
dose
50 mg
mode of admin.
Oral with 240 mL of water after an overnight fast of at least 10 h


Boehringer Ingelheim
09 Sep 2019
BI Trial No.: 1371-0005
c26448055-04
Trial Protocol
Page 3 of 67
Proprietary confidential information © 2019 Boehringer Ingelheim International GmbH or one or more of its affiliated companies
001-MCS-40-106-RD-13 (6.0) / Saved on: 13 Jun 2018
Test product 2
Eremfat® 600 mg film-coated tablet (rifampicin; strength: 600 mg)
dose
600 mg once daily (qd) for 7 days in treatment T
mode of admin.
Oral with 240 mL of water 
Duration of treatment
Treatment period 1: 
Treatment period 2: 
50 mg BI 894416 as single dose on Day 1 (Reference – R)
600 mg Eremfat® as single dose for 7 days (Days -7 to -1)
50 mg BI 894416 as single dose on Day 1
(Test – T)
Statistical methods
Relative bioavailability will be estimated by the ratios of the geometric means 
(test/reference) for the primary and secondary endpoints. Additionally, their two-
sided 90% confidence intervals (CIs) will be provided. This method corresponds to 
the two one-sided t-test procedure, each at a 5% significance level. Since the main 
focus is on estimation and not testing, a formal hypothesis test and associated 
acceptance range is not specified. The statistical model will be mixed effects model 
on the logarithmic scale including effects for subject (random) and treatment
(fixed). CIs will be calculated based on the residual error from the mixed effects 
model.
Descriptive statistics will be calculated for all endpoints.


Boehringer Ingelheim
09 Sep 2019
BI Trial No.: 1371-0005
c26448055-04
Trial Protocol
Page 4 of 67
Proprietary confidential information © 2019 Boehringer Ingelheim International GmbH or one or more of its affiliated companies
001-MCS-40-106-RD-13 (6.0) / Saved on: 13 Jun 2018
FLOW CHART
Period
Visit
Day
Planned time (relative to 
BI 894416 administration)
[h:min]
Approximate clock time  of 
actual day [h:min]
Event and comment
Safety laboratory 7
PK blood BI 894416
PK blood rifampicin
PK urine BI 894416 11
12-lead ECG
Neurological examination 8
Vital signs (BP, PR)
Questioning for AEs and 
concomitant therapy 6
SCR
1
-21 to -2
Screening (SCR)1
A
x
x
x
2
-1
-14:00
18:00
Admission to trial site
x10
1 (BI 894416 alone)
1
-2:00
06:00
Allocation to study subject 
numbers2
B2,12
x2
x2
x2
x2
x2
0:00
08:00
BI 894416 administration
▲
0:15
08:15
x
│
0:30
08:30
x
│
0:45
08:45
x
│
1:00
09:00
x
│
x
x
1:30
09:30
x
│
2:00
10:00
240 mL fluid intake
x
│
x
x
x
2:30
10:30
x
│
3:00
11:00
x
│
4:00
12:00
240 mL fluid intake, thereafter 
lunch3
x
┼
│
x
6:00
14:00
x
│
8:00
16:00
Snack (voluntary)3
x
┼
│
10:00
18:00
x
│
11:00
19:00
Dinner
│
12:00
20:00
x
┼
│
x 
2
24:00
08:00
Discharge from trial site, 
breakfast3 (voluntary)
B
x
▼
x
x
x
34:00
18:00
Ambulatory visit
x
x
3
48:00
08:00
Ambulatory visit
x
x
2 (BI 894416 + rifampicin)
3
-7
-158:30
17:30
Admission to trial site2
x2,10
x2
-158:00
18:00
Rifampicin administration
-157:00
19:00
Dinner
-156:00
20:00
Discharge from trial site
x
-6
-134:00
18:00
Ambulatory visit, 
rifampicin administration
x
-5
-110:00
18:00
Ambulatory visit, 
rifampicin administration
x
-4
-86:00
18:00
Ambulatory visit, 
rifampicin administration
x
-3
-62:00
18:00
Ambulatory visit, 
rifampicin administration
x9
x
-2
-38:00
18:00
Ambulatory visit, 
rifampicin administration
C9
x9
x
-1
-14:30
17:30
Admission to trial site2
x2
-14:00
18:00
Rifampicin administration
x9
-13:00
19:00
Dinner
-12:00
20:00
x


Boehringer Ingelheim
09 Sep 2019
BI Trial No.: 1371-0005
c26448055-04
Trial Protocol
Page 5 of 67
Proprietary confidential information © 2019 Boehringer Ingelheim International GmbH or one or more of its affiliated companies
001-MCS-40-106-RD-13 (6.0) / Saved on: 13 Jun 2018
FLOW CHART (cont’d)
Period
Visit
Day
Planned time (relative to 
BI 894416 administration)
[h:min]
Approximate clock time  of 
actual day [h:min]
Event and comment
Safety laboratory 7
PK blood BI 894416
PK blood rifampicin
PK urine BI 894416 11
12-lead ECG
Neurological examination 8
Vital signs (BP, PR)
Questioning for AEs and 
concomitant therapy 6
2 (BI 894416 + rifampicin)
3
1
-2:00
06:00
B2
x2
x2
x2
x2
x2
0:00
08:00
BI 894416 administration
▲
0:15
08:15
x
│
0:30
08:30
x
│
0:45
08:45
x
│
1:00
09:00
x
│
x
x
1:30
09:30
x
│
2:00
10:00
240 mL fluid intake
x
│
x
x
x
2:30
10:30
x
│
3:00
11:00
x
│
4:00
12:00
240 mL fluid intake, thereafter 
lunch3
x
┼
│
x
6:00
14:00
x
│
8:00
16:00
Snack (voluntary)3
x
┼
10:00
18:00
x
│
11:00
19:00
Dinner
│
12:00
20:00
x
┼
x 
2
24:00
08:00
Discharge from trial site, 
breakfast3 (voluntary)
B
x
▼
x
x
x
34:00
18:00
Ambulatory visit
x
x
3
48:00
08:00
Ambulatory visit
x
x
FU
4
8 to 15
End of trial (EoTrial)
examination4
B
x
x
x
x
1.
Subject must be informed and written informed consent obtained prior to starting any screening procedures. Screening 
procedures include physical examination, neurological examination, check of vital signs, ECG, safety laboratory 
(including drug screening and Cotinine test), demographics (including determination of body height and weight, 
smoking status and alcohol history), relevant medical history, concomitant therapy and review of inclusion/exclusion 
criteria.
2.
The time is approximate; the procedure is to be performed and completed within the 3 h prior to the next drug 
administration.
3.
If several actions are indicated at the same time, the intake of meals will be the last action.
4.
At the end of trial visit the EoTrial examination includes physical examination, neurological examination, vital signs, 
ECG, safety laboratory, recording of AEs and concomitant therapies.
5.
Including urine drug screening and alcohol breath test
6.
AEs and concomitant therapies will be recorded throughout the trial, but will be specifically asked for at the times
indicated in the Flow Chart above.
7.
Letters A, B, and C define different sets of safety laboratory examinations (see Section 5.2.3)
8.
Unscheduled neurological examinations may be added at any time during the trial for individual volunteers or the whole 
treatment group, e.g., in case of neurological adverse events, if assessed as necessary by the investigator.
9.
Within 15 min of next drug administration
10. Only urine drug screening and alcohol breath test
11. A blank urine sample (x) is to be obtained prior to administration of trial medication. Other urine samples are to be 
collected over the stated post-dose intervals (◄––│––│––►) 0-4, 4-8, 8-12, and 12-24 h.
12. Pharmacogenetic samples will be collected at Day 1 prior to administration.


Boehringer Ingelheim
09 Sep 2019
BI Trial No.: 1371-0005
c26448055-04
Trial Protocol
Page 6 of 67
Proprietary confidential information © 2019 Boehringer Ingelheim International GmbH or one or more of its affiliated companies
001-MCS-40-106-RD-13 (6.0) / Saved on: 13 Jun 2018
TABLE OF CONTENTS
TITLE PAGE ......................................................................................................1
CLINICAL TRIAL PROTOCOL SYNOPSIS ................................................2
FLOW CHART...................................................................................................4
TABLE OF CONTENTS ...................................................................................6
ABBREVIATIONS.......................................................................................... 10
1.
INTRODUCTION.................................................................................... 13
1.1
MEDICAL BACKGROUND............................................................................13
1.2
DRUG PROFILE...............................................................................................14
1.2.1
BI 894416 ...............................................................................................14
1.2.2
Rifampicin .............................................................................................14
1.2.3
Residual Effect Period..........................................................................15
1.3
RATIONALE FOR PERFORMING THE TRIAL........................................16
1.4
BENEFIT - RISK ASSESSMENT ...................................................................16
1.4.1
Expected benefit to the target population...........................................16
1.4.2
Procedure-related risks ........................................................................17
1.4.3
Drug-related risks and safety measures..............................................17
1.4.3.1
Risks related to BI 894416.......................................................17
1.4.3.2
Risks related to rifampicin.......................................................20
1.4.3.3
Risks related to combined administration of BI 894416 and 
rifampicin.................................................................................21
1.4.3.4
Drug-induced liver injury ........................................................21
1.4.4
Overall assessment of benefit-risk ratio..............................................22
2.
TRIAL OBJECTIVES AND ENDPOINTS........................................... 23
2.1
MAIN OBJECTIVES, PRIMARY AND SECONDARY ENDPOINTS ......23
2.1.1
Main objectives......................................................................................23
2.1.2
Primary endpoints ................................................................................23
2.1.3
Secondary endpoint ..............................................................................23
3.
DESCRIPTION OF DESIGN AND TRIAL POPULATION.............. 25
3.1
OVERALL TRIAL DESIGN AND PLAN ......................................................25
3.2
DISCUSSION OF TRIAL DESIGN, INCLUDING THE CHOICE OF 
CONTROL GROUP..........................................................................................25
3.3
SELECTION OF TRIAL POPULATION ......................................................26


Boehringer Ingelheim
09 Sep 2019
BI Trial No.: 1371-0005
c26448055-04
Trial Protocol
Page 7 of 67
Proprietary confidential information © 2019 Boehringer Ingelheim International GmbH or one or more of its affiliated companies
001-MCS-40-106-RD-13 (6.0) / Saved on: 13 Jun 2018
3.3.1
Main diagnosis for trial entry..............................................................26
3.3.2
Inclusion criteria...................................................................................26
3.3.3
Exclusion criteria ..................................................................................26
3.3.4
Withdrawal of subjects from treatment or assessments ...................28
3.3.4.1
Discontinuation of trial treatment............................................28
3.3.4.2
Withdrawal of consent to trial participation ............................29
3.3.4.3
Discontinuation of the trial by the sponsor..............................29
3.3.5
Replacement of subjects .......................................................................29
4.
TREATMENTS........................................................................................ 30
4.1
INVESTIGATIONAL TREATMENTS ..........................................................30
4.1.1
Identity of the Investigational Medicinal Products ...........................30
4.1.2
Selection of doses in the trial................................................................30
4.1.3
Method of assigning subjects to treatment groups ............................31
4.1.4
Drug assignment and administration of doses for each subject .......32
4.1.5
Blinding and procedures for unblinding ............................................33
4.1.6
Packaging, labelling, and re-supply ....................................................33
4.1.7
Storage conditions.................................................................................33
4.1.8
Drug accountability ..............................................................................33
4.2
OTHER TREATMENTS, EMERGENCY  PROCEDURES,
RESTRICTIONS ...............................................................................................34
4.2.1
Other treatments and emergency procedures....................................34
4.2.2
Restrictions............................................................................................34
4.2.2.1
Restrictions regarding concomitant treatment .........................34
4.2.2.2
Restrictions on diet and life style.............................................34
4.3
TREATMENT COMPLIANCE.......................................................................35
5.
ASSESSMENTS....................................................................................... 36
5.1
ASSESSMENT OF EFFICACY.......................................................................36
5.2
ASSESSMENT OF SAFETY............................................................................36
5.2.1
Physical examination ............................................................................36
5.2.2
Vital signs...............................................................................................36
5.2.3
Safety laboratory parameters..............................................................36
5.2.4
Electrocardiogram................................................................................38
5.2.5
Other safety parameters.......................................................................39
5.2.5.1
Neurological examination........................................................39
5.2.6
Assessment of adverse events...............................................................40
5.2.6.1
Definitions of adverse events...................................................40


Boehringer Ingelheim
09 Sep 2019
BI Trial No.: 1371-0005
c26448055-04
Trial Protocol
Page 8 of 67
Proprietary confidential information © 2019 Boehringer Ingelheim International GmbH or one or more of its affiliated companies
001-MCS-40-106-RD-13 (6.0) / Saved on: 13 Jun 2018
Adverse event ............................................................40
5.2.6.1.1
Serious adverse event ................................................40
5.2.6.1.2
AEs considered ‘Always Serious’.............................40
5.2.6.1.3
Adverse events of special interest .............................41
5.2.6.1.4
Intensity (severity) of AEs.........................................42
5.2.6.1.5
Causal relationship of AEs ........................................42
5.2.6.1.6
5.2.6.2
Adverse event collection and reporting ...................................43
AE collection.............................................................43
5.2.6.2.1
AE reporting to the sponsor and timelines ................44
5.2.6.2.2
Information required..................................................44
5.2.6.2.3
5.3
DRUG CONCENTRATION MEASUREMENTS AND 
PHARMACOKINETICS..................................................................................44
5.3.1
Assessment of pharmacokinetics .........................................................44
5.3.2
Methods of sample collection...............................................................44
5.3.2.1
Blood sampling for pharmacokinetic analysis.........................44
5.3.3
Analytical determinations ....................................................................46
5.3.3.1
Analytical determination of analyte plasma concentration......46
5.3.3.2
Analytical determination of analyte urine concentration.........47
5.4
BIOBANKING ...................................................................................................47
5.6
APPROPRIATENESS OF MEASUREMENTS.............................................47
6.
INVESTIGATIONAL PLAN.................................................................. 48
6.1
VISIT SCHEDULE............................................................................................48
6.2
DETAILS OF TRIAL PROCEDURES AT SELECTED VISITS ................48
6.2.1
Screening period....................................................................................48
6.2.2
Treatment periods.................................................................................48
6.2.3
Follow-up period and trial completion ...............................................49
7.
STATISTICAL METHODS AND DETERMINATION OF
SAMPLE SIZE......................................................................................... 50
7.1
STATISTICAL DESIGN – MODEL ...............................................................50
7.2
NULL AND ALTERNATIVE HYPOTHESES ..............................................50
7.3
PLANNED ANALYSES....................................................................................50
7.3.1
Primary endpoint analyses...................................................................51
7.3.2
Secondary endpoint analyses ...............................................................52
7.3.4
Safety analyses.......................................................................................53
7.4
INTERIM ANALYSES .....................................................................................54
7.5
HANDLING OF MISSING DATA ..................................................................54
7.5.1
Safety......................................................................................................54


Boehringer Ingelheim
09 Sep 2019
BI Trial No.: 1371-0005
c26448055-04
Trial Protocol
Page 9 of 67
Proprietary confidential information © 2019 Boehringer Ingelheim International GmbH or one or more of its affiliated companies
001-MCS-40-106-RD-13 (6.0) / Saved on: 13 Jun 2018
7.5.2
Pharmacokinetics..................................................................................54
7.6
RANDOMISATION ..........................................................................................54
7.7
DETERMINATION OF SAMPLE SIZE ........................................................54
8.
INFORMED CONSENT, TRIAL RECORDS, DATA 
PROTECTION, PUBLICATION POLICY, AND 
ADMINISTRATIVE STRUCTURE...................................................... 56
8.1
TRIAL APPROVAL, SUBJECT INFORMATION, INFORMED 
CONSENT ..........................................................................................................56
8.2
DATA QUALITY ASSURANCE .....................................................................57
8.3
RECORDS..........................................................................................................57
8.3.1
Source documents .................................................................................57
8.3.2
Direct access to source data and documents.......................................58
8.3.3
Storage period of records.....................................................................58
8.4
EXPEDITED REPORTING OF ADVERSE EVENTS .................................58
8.5
STATEMENT OF CONFIDENTIALITY AND SUBJECT PRIVACY.......58
8.5.1
Collection, storage and future use of biological samples and 
corresponding data ...............................................................................59
8.6
TRIAL MILESTONES .....................................................................................59
8.7
ADMINISTRATIVE STRUCTURE OF THE TRIAL ..................................60
9.
REFERENCES......................................................................................... 61
9.1
PUBLISHED REFERENCES...........................................................................61
9.2
UNPUBLISHED REFERENCES.....................................................................62
10. APPENDICES .......................................................................................... 64
11. DESCRIPTION OF GLOBAL AMENDMENT(S).............................. 65
11.1
GLOBAL AMENDMENT (REVISED PROTOCOL)...................................65
11.2
GLOBAL AMENDMENT 2 .............................................................................66
11.3
GLOBAL AMENDMENT 3 .............................................................................67


Boehringer Ingelheim
09 Sep 2019
BI Trial No.: 1371-0005
c26448055-04
Trial Protocol
Page 10 of 67
Proprietary confidential information © 2019 Boehringer Ingelheim International GmbH or one or more of its affiliated companies
001-MCS-40-106-RD-13 (6.0) / Saved on: 13 Jun 2018
ABBREVIATIONS
ADME
Absorption, distribution, metabolism, and excretion
ADP
Adenosine diphosphate
AE
Adverse event
AESI
Adverse events of special interest
ALCOA
Attributable, legible, contemporaneous, original, and accurate
AUC0-∞
Area under the concentration-time curve of the analyte in plasma over the 
time interval from 0 extrapolated to infinity
 
AUC0-tz
Area under the concentration-time curve of the analyte in plasma over the 
time interval from 0 to the last quantifiable data point
BA
Bioavailability
BI
Boehringer Ingelheim
BMI
Body mass index (weight divided by height squared)
BP
Blood pressure
CA
Competent authority
CI
Confidence interval
 
 
 
 
Cmax
Maximum measured concentration of the analyte in plasma
CRF
Case Report Form, paper or electronic (sometimes referred to as ‘eCRF’)
CTM
Clinical Trial Manager
CTP
Clinical Trial Protocol
CTR
Clinical Trial Report
CYP
Cytochrome P450 superfamily
CYP1A1
Cytochrome P450 isoenzyme 1A1
CYP2B6
Cytochrome P450 isoenzyme 2B6
CYP2C19
Cytochrome P450 isoenzyme 2C19
CYP2C8
Cytochrome P450 isoenzyme 2C8
CYP2C9
Cytochrome P450 isoenzyme 2C9


Boehringer Ingelheim
09 Sep 2019
BI Trial No.: 1371-0005
c26448055-04
Trial Protocol
Page 11 of 67
Proprietary confidential information © 2019 Boehringer Ingelheim International GmbH or one or more of its affiliated companies
001-MCS-40-106-RD-13 (6.0) / Saved on: 13 Jun 2018
CYP3A
Cytochrome P450 subfamily 3A
CYP3A4
Cytochrome P450 isoenzyme 3A4
DILI
Drug induced liver injury
DNA
Deoxyribonucleic acid
EC
Ethics Committee
ECG
Electrocardiogram
eCRF
Electronic case report form
eDC
Electronic data capture 
EDTA
Ethylenediaminetetraacetic acid
EEG
Electroencephalogram
EoTrial
End of trial
EudraCT
European Clinical Trials Database
FDA
Food and Drug Administration
 
FU
Follow-up
GCP
Good Clinical Practice
gCV
Geometric coefficient of variation
gMean
Geometric mean
HPC
Human Pharmacology Centre
IB
Investigator’s Brochure
ICF
Informed Consent Form
IEC
Independent Ethics Committee
IPV
Important Protocol Violation
IQRMP
Integrated Quality and Risk Management Plan
IRB
Institutional Review Board
ISF
Investigator Site File
LC-MS/MS
Liquid chromatography with tandem mass spectrometry
MDA
Methylenedioxyamphetamine
MDMA
Methylenedioxymethamphetamine
MedDRA
Medical Dictionary for Regulatory Activities
MRT,ex
Mean residence time of the analyte in the body, extravascular
NK cell
Natural killer cell
PE
Polyethylene
PK
Pharmacokinetic(s)
PKS
Pharmacokinetic set
PP
Polypropylene


Boehringer Ingelheim
09 Sep 2019
BI Trial No.: 1371-0005
c26448055-04
Trial Protocol
Page 12 of 67
Proprietary confidential information © 2019 Boehringer Ingelheim International GmbH or one or more of its affiliated companies
001-MCS-40-106-RD-13 (6.0) / Saved on: 13 Jun 2018
PR
Pulse rate
q.d.
Once daily
QT
Time between start of the Q-wave and the end of the T-wave in an 
electrocardiogram
QTc
QT interval corrected for heart rate using the method of Fridericia (QTcF) 
or Bazett (QTcB)
R
Reference treatment
REP
Residual effect period
RNA
Ribonucleic acid
SAE
Serious Adverse Event
SCR
Screening
SPC
Summary of Product Characteristics
SOP
Standard Operating Procedure
SRD
Single-rising dose
SUSAR
Suspected unexpected serious adverse reaction
SYK
Spleen tyrosine kinase
T
Test product or treatment
 
TS
Treated set
TSAP
Trial statistical analysis plan
ULN
Upper limit of normal
 
WOCBP
Woman of child bearing potential
XTC
Ecstasy 


Boehringer Ingelheim
09 Sep 2019
BI Trial No.: 1371-0005
c26448055-04
Trial Protocol
Page 13 of 67
Proprietary confidential information © 2019 Boehringer Ingelheim International GmbH or one or more of its affiliated companies
001-MCS-40-106-RD-13 (6.0) / Saved on: 13 Jun 2018
1.
INTRODUCTION
BI 894416 is an oral, selective non-receptor protein tyrosine kinase SYK (spleen tyrosine 
kinase) inhibitor under clinical development for the indication of uncontrolled severe 
persistent asthma.
This trial will be performed to investigate the effect of multiple oral doses of the strong 
CYP3A inducer rifampicin [R18-0241] on the single dose pharmacokinetics of BI 894416. 
1.1
MEDICAL BACKGROUND
Asthma is a heterogenous disease characterized by a chronic inflammatory process of the 
airways and driven by both the innate and adaptive immune pathways [R14-4230, 
P08-01263]. In severe asthma, the T type 2 inflammation (T2) -high and T2-low, and the 
non-T2 pathways are involved associated with a mixed pattern of inflammation involving 
eosinophil, basophil, mast, neutrophil, innate lymphoid and dendritic cells [R15-5888, R16-
0945].
SYK is a non-receptor cytoplasmic tyrosine kinase that is predominantly expressed in cells of 
hematopoietic lineage, including B cells, T cells, monocytes, NK cells, mast cells, basophils, 
and neutrophils [R15-5470]. SYK is a key component of the signal transduction associated 
with the T2-high and T2-low, and non-T2 asthma pathways that is activated through 
interaction with allergens and a number of innate and adaptive immune receptors including 
Fc receptors on basophils, mast, B- and T cells. SYK is essential for the FcεR1-mediated 
activation and degranulation of mast cells and basophils. SYK is also important in the signal 
propagation of the dectin family of innate receptors, present on macrophages, dendritic cells 
and neutrophils. Furthermore, SYK has important roles in B-cell and T-cell development, 
with partially redundant functions with Zeta-chain-associated protein kinase of 70 kDa 
(ZAP70) [R15-5470, R16-5298].
For more details on medical background see the current version of the Investigator’s 
Brochure (IB) [c03536505-04].


Boehringer Ingelheim
09 Sep 2019
BI Trial No.: 1371-0005
c26448055-04
Trial Protocol
Page 14 of 67
Proprietary confidential information © 2019 Boehringer Ingelheim International GmbH or one or more of its affiliated companies
001-MCS-40-106-RD-13 (6.0) / Saved on: 13 Jun 2018
1.2
DRUG PROFILE
1.2.1
BI 894416
BI 894416 is a potent and selective inhibitor of SYK. Based on pre-clinical in vitro and in 
vivo data, SYK inhibition is expected to have effect on the non-T2 and T2 inflammatory 
pathway components of severe asthma.
So far, BI 894416 was investigated in one clinical phase I first-in-man trial (BI study number 
1371-0001) and one clinical phase I drug-drug interaction trial (BI study number 1371-0004) 
in healthy male volunteers. 
Trial 1371-0001 consisted of two trial parts, a single-rising dose (SRD) part and a relative 
bioavailability (rel BA) part. Single-dose treatment with up to 70 mg BI 894416 or placebo as 
oral solution in the SRD part of trial 1371-0001 as well as administration of three single 
doses (10, 10, and 40 mg BI 894416) as tablet or oral solution in the rel BA part was safe and 
well tolerated. For details on safety and tolerability as well as on pharmacokinetics and 
biomarker data of trial 1371-0001 refer to the IB [c03536505-04]. 
Trial 1371-0004 investigated the effect of strong inhibition of CYP3A and inhibition of 
P-glycoprotein on an oral single dose of BI 894416. In that trial 3 mg BI 894416 was given 
without (period 1) or together with 200 mg itraconazole q.d. (period 2; 3 days pre-treatment, 
a fourth dose of itraconazole 1 h before BI 894416, and a fifth dose of itraconazole 23 h 
following BI 894416 dosing). Preliminary PK data (based on planned time points) indicate 
that the ratios of Cmax, AUC0-tz and AUC0-∞of BI 894416 in plasma when given together with 
itraconazole and when given alone were 113.32%, 141.96%, and 142.92%, respectively. 
BI 894416, alone or together with itraconazole, was assessed as safe and well-tolerated in 
trial 1371-0004. For more details refer to the IB [c03536505-04].
For a more detailed description of the BI 894416 profile, please refer to the current 
Investigator’s Brochure (IB) [c03536505-04]. 
1.2.2
Rifampicin
Rifampicin is a broad-spectrum antibiotic that can be used to treat infections such as 
tuberculosis, leprosy, and other mycobacterial infections, and for prophylaxis of e.g. 
meningococcal meningitis [R19-2541]. Rifampicin inhibits bacterial RNA polymerase. The 
dosage of rifampicin in adults in the treatment of tuberculosis is usually between 450 and 600 
mg/day [R19-2541].
FDA recommends rifampicin as strong index inducer of CYP3A and CYP2C19 and as 
moderate index inducer of CYP2B6, CYP2C8, and CYP2C9 [R18-0241]. 
Pharmacokinetics
Rifampicin is readily absorbed from the gastrointestinal tract. Intake of rifampicin with a 
high-fat meal may reduce Cmax and AUC by 25-30% and by 6-23%, respectively, and may 
delay tmax by a factor of 2. Rifampicin has a large volume of distribution, and approximately 
70-90% is plasma-protein bound. Rifampicin is metabolized in the liver by CYP enzymes to 


Boehringer Ingelheim
09 Sep 2019
BI Trial No.: 1371-0005
c26448055-04
Trial Protocol
Page 15 of 67
Proprietary confidential information © 2019 Boehringer Ingelheim International GmbH or one or more of its affiliated companies
001-MCS-40-106-RD-13 (6.0) / Saved on: 13 Jun 2018
its main metabolite 25 desacetyl rifampicin. Due to rifampicin-mediated induction of CYP
enzymes, plasma elimination half-life of rifampicin decreases with multiple-dose 
administration. Elimination half-life of rifampicin may be between 3 and 16 hours and is 
influenced by enterohepatic circulation. [R19-2541]
Rifampicin induces a number of drug-metabolising enzymes, having the greatest effects on 
the expression of CYP3A4 in the liver and in the small intestine. It induces several other CYP 
enzymes as well including CYP2C19, 2B6, 2C8 and 2C9 [R18-0241]. In addition, rifampicin 
induces some drug transporters, such as intestinal P-glycoprotein [P14-07656]. 
Full induction of drug-metabolising enzymes may be reached in about 1 week after starting 
rifampicin treatment, and the induction may dissipate in roughly 2 weeks after discontinuing 
rifampicin [P03-08008]. 
Safety
Very common adverse reactions to rifampicin are elevations of liver enzymes. In some 
patients hyperbilirubinaemia can occur in the early days of treatment. This is thought to result
from competition between rifampicin and bilirubin for hepatic excretion. Very rarely, acute 
hepatitis is caused by rifampicin. Monitoring of liver function tests is recommended.
Common adverse reactions are gastro-intestinal reactions including anorexia, nausea, 
vomiting, abdominal pain, meteorism, and diarrhoea as well as mild hypersensitivity 
reactions such as fever, erythema exsudativum multiforme, itching with or without skin rash, 
and urticaria. More serious hypersensitivity reactions have been reported but are rare 
(dyspnea, asthma-like episodes, pulmonary edema, other edema, anaphylactic shock) or very 
rare (lupus-like syndrome, flu syndrome, severe allergic skin reactions). Pseudomembranous 
colitis has been reported with rifampicin therapy in very rare cases. 
For a more detailed description of rifampicin please refer to the current version of the 
summary of product characteristics (SPC) [R19-2541].
1.2.3
Residual Effect Period
The Residual Effect Period (REP, i.e., the period after the last dose with measurable drug 
levels and/or pharmacodynamic effects still likely to be present) of BI 894416 has not been 
defined yet. However, the elimination half-life of BI 894416 is short (gMean terminal half-
life between 2.96 and 5.31 h in the SRD part of trial 1371-0001), the mode of action is 
reversible, and safety and tolerability in previous trial 1371-0001 were good. This suggests 
that the occurrence of any potential adverse effects would likely be of short duration (i.e. few 
days). When given together with rifampicin, it is expected that plasma exposure of BI 894416 
could be decreased as a result of CYP enzyme and/or P-glycoprotein induction and the time 
of relevant plasma exposure could be shortened. An increase of BI 894416 plasma exposure 
when given with rifampicin in this trial is not expected.
The follow-up visit is earliest on Day 8 following BI 894416 dosing in period 2, as this is 
expected to cover the period in which any potential adverse effects could reasonably occur.
For the use of rifampicin in this trial, the REP is defined as 6 days.


Boehringer Ingelheim
09 Sep 2019
BI Trial No.: 1371-0005
c26448055-04
Trial Protocol
Page 16 of 67
Proprietary confidential information © 2019 Boehringer Ingelheim International GmbH or one or more of its affiliated companies
001-MCS-40-106-RD-13 (6.0) / Saved on: 13 Jun 2018
1.3
RATIONALE FOR PERFORMING THE TRIAL
Based on in vitro data, CYP3A is major responsible enzyme for metabolism of BI 894416. 
 
Preliminary results of drug-drug interaction trial 1371-0004 indicated only a minor increase 
of BI 894416 plasma exposure parameters when given with itraconazole (see Section 1.2.1). 
However, the extent of the effect of concomitant administration of a CYP3A and 
P-glycoprotein inducer on BI 894416 pharmacokinetics is unclear. Assessment is necessary 
to inform concomitant treatment recommendations in patient studies.
This clinical trial will be performed to investigate the effect of multiple doses of rifampicin
on the pharmacokinetics of a single dose of BI 894416 in order to assess if and to which 
extent the pharmacokinetics of BI 894416 are affected by induction of CYP3A.
Rifampicin is chosen for this trial as perpetrator drug, as this drug is recommended as strong 
index inducer of CYP3A by FDA [R18-0241]. 
1.4
BENEFIT - RISK ASSESSMENT
Participation in this clinical trial is without any (therapeutic) benefit for healthy subjects. 
Their participation, however, is of major importance for the development of BI 894416.
Subjects are exposed to risks of study procedures and risks related to the exposure to the trial 
medication.
1.4.1
Expected benefit to the target population
Asthma is a heterogeneous disease that is driven by the innate and adaptive immune pathway.
In severe asthma, both the T2-high and T2-low, and the non-T2 inflammation pathways are 
involved, and associated with a mixed pattern of inflammation involving eosinophil, 
basophil, mast, neutrophil, innate lymphoid and dendritic cells. Up to 50% of severe asthma 
is driven by the non T2 and/or T2-low alone or in combination with the T2-high pathway. 
This non T2 / T2-low component represents an area of unmet medical need that does not 
respond to high dose inhaled corticosteroids or other current controller therapy, and is 
unlikely to respond to the T2-high monoclonal antibodies targeted therapies. 
SYK is a key component of signal transduction associated with the T2-high and T2-low, and
non-T2 asthma pathways that is activated through interaction with allergens and a number of
innate and adaptive immune receptors including Fc receptors on basophils, mast, B and T
cells. SYK is also important in the signal propagation of the dectin family of innate receptors,
present on macrophages, dendritic cells and neutrophils.
Such a therapy would meet a substantial unmet need for severe asthma patients, especially
those with a non T2 and/or T2-low component, whether early/late-onset or steroid resistant,
and could become a safe and effective alternate also in T2 asthma to high dose inhaled 
corticosteroids, oral systemic corticosteroids or T2-high biological monoclonal antibodies.


Boehringer Ingelheim
09 Sep 2019
BI Trial No.: 1371-0005
c26448055-04
Trial Protocol
Page 17 of 67
Proprietary confidential information © 2019 Boehringer Ingelheim International GmbH or one or more of its affiliated companies
001-MCS-40-106-RD-13 (6.0) / Saved on: 13 Jun 2018
1.4.2
Procedure-related risks
The use of an indwelling venous catheter or venepuncture for e.g. blood sampling may result 
in mild bruising, and in rare cases, in transient inflammation of the wall of the vein, or nerve 
injury, potentially resulting in paraesthesia, reduced sensibility, and/or pain for an indefinite 
period.
ECG electrodes may cause local and typically transient skin reactions.
The total volume of blood withdrawn per subject during the entire study will not exceed the 
volume of a normal blood donation (500 mL). No health-related risk to healthy subjects is 
expected from withdrawal of this volume of blood.
1.4.3
Drug-related risks and safety measures
1.4.3.1
Risks related to BI 894416
Potential effects on immune cells
SYK is involved in the function of basophil, mast, neutrophil and dendritic cells. Moreover, 
SYK is implicated in the development and function of both T cells and B cells. For details 
refer to the IB [c03536505-04].
The risk for healthy volunteers due to effects of BI 894416 on immune cells is expected to be 
minimal, for the following reasons:

Inhibition of SYK is not expected to have a negative effect with regards to the 
immune response of innate immune cells to viral or bacterial infections due to
redundancy in the infection immune response. The key neutrophil and dendritic cell 
functions most likely will be triggered by alternative pathways.

Safety and tolerability data of trial 1371-0001 are not suggestive of an increased risk 
of infectious adverse events or of any relevant BI 894416-related findings in WBC, 
differential blood count, immunoglobulins, or lymphocyte subpopulations after single 
doses up to 70 mg BI 894416 (see also IB [c03536505-04]).

Due to the reversible mode of action of BI 894416 with regards to SYK inhibition, 
any potential effects on immune cells are expected to be of transient nature.
Risk mitigation and monitoring: Subjects with a history or diagnosis of relevant 
immunological disease will be excluded from trial participation (see Section 3.3.3). Adverse 
events will be monitored for an increase in infectious adverse events. Safety laboratory 
contains WBC, differential blood count, and CRP.
Tumour biology and carcinogenicity
The SYK pathway has been hypothesized to act as both a tumour suppressor and a tumour
promoter in different types of human cancers [R16-4459]. An increased risk of 
carcinogenic/metastatic potential in epithelial cancers has been reported in the literature 
related to SYK knock-out, but not related to SYK inhibition. Allelic deletion of SYK has 


Boehringer Ingelheim
09 Sep 2019
BI Trial No.: 1371-0005
c26448055-04
Trial Protocol
Page 18 of 67
Proprietary confidential information © 2019 Boehringer Ingelheim International GmbH or one or more of its affiliated companies
001-MCS-40-106-RD-13 (6.0) / Saved on: 13 Jun 2018
been associated with breast adenocarcinoma [R15-4770]. However, there is no evidence that 
pharmacologic inhibition of SYK will increase carcinogenicity or metastatic risk. Preclinical 
data with a potent and selective tool SYK inhibitor, BI 1002494, are in line with an absence 
of a carcinogenic effect due to inhibition of SYK enzymatic function [n00243171]. 
Risk mitigation and monitoring: Only male subjects are included in this trial. In view of the 
extended time necessary to induce a carcinogenic effect, two single doses of BI 894416 are
not considered a relevant carcinogenic risk to male subjects participating in this study. 
Accordingly, no further risk mitigation is required in this study.
Platelet aggregation and bleeding risk
A role of SYK in platelet function has been demonstrated in literature [R15-5470]. Several 
platelet functions rely on SYK signalling (e.g. collagen receptor GPVI) but others are 
independent of SYK [R16-5240]. In vitro studies using human platelets demonstrated that at 
concentrations up to 100 μM, BI 894416 had no effect on extrinsic or intrinsic coagulation 
pathways. Also, BI 894416 did not inhibit ADP-induced platelet aggregation up to 100 μM. 
However, BI 894416 inhibited collagen- and arachidonic acid-induced platelet aggregation at 
3 μM and 5 μM. However, platelet function as measured by bleeding time is not affected by a 
drug unless all the platelet pathways are inhibited due to redundancy within the system. 
Therefore, no risk for bleeding exists with regard to platelet inhibition unless a subject is also 
on another antiplatelet drug that blocks these other pathways. In line with this conclusion, 
data of previous trial 1371-0001 do not indicate any signs of an increased risk of bleeding.
Risk mitigation and monitoring: Use of any other concomitant drug that could reasonably 
inhibit platelet aggregation or coagulation (e.g. acetylsalicylic acid) will be prohibited (see 
Sections 3.3.3 and 4.2.2.1). Adverse events will be monitored for any signs of bleeding or 
bleeding-related adverse events.
Bone density
SYK is reported to be involved in osteoclast differentiation, development and function. For 
details see the IB [c03536505-04]. In this trial, each subject is treated with two single doses 
of BI 894416. Due to comparatively slow turnover of bone tissue, no relevant effect on bone 
is expected due to two single-dose administrations with BI 894416 in this trial, and no 
specific monitoring of bone density is necessary or reasonable in this trial.
Mortality / morbidity in preclinical studies
Mortality / sacrifice due to morbidity occurred in CByB6F1 non-transgenic mice and in 
Wistar Han rats. Clinical signs preceding morbidity were similar in both rodent species and 
included respiratory changes (rapid, shallow, and/or labored breathing), decreased motor 
activity, ruffled fur, hunched or prostrate posture, eye changes (squinting, discharge) and/or 
hypothermia. One humane sacrifice due to overt neurotoxicity was done in one dog of the 
3-day escalation study. For details see the current version of the IB [c03536505-04]. 
Risk mitigation and monitoring: Data of previous trial 1371-0001 indicate good safety and 
tolerability of BI 894416 at all investigated doses (single oral doses up to 70 mg). The dose of 


Boehringer Ingelheim
09 Sep 2019
BI Trial No.: 1371-0005
c26448055-04
Trial Protocol
Page 19 of 67
Proprietary confidential information © 2019 Boehringer Ingelheim International GmbH or one or more of its affiliated companies
001-MCS-40-106-RD-13 (6.0) / Saved on: 13 Jun 2018
BI 894416 given in this trial is lower than doses given previously to healthy volunteers, and 
no increase of exposure of BI 894416 is expected when given with rifampicin. That means, 
BI 894416 plasma exposures expected in this trial are in the range measured previously in 
trial 1371-0001 and that were associated with good safety and tolerability. Moreover, subjects 
will be in-house at the trial site under close medical observation for 24 h after administration 
of BI 894416. Vital signs and ECGs will be measured during the trial, and subjects will be 
instructed to report AEs spontaneously and will be asked at pre-defined time points for AEs. 
In case of AEs in need of treatment, the investigator can authorise symptomatic therapy. In 
those cases, subjects will be treated as necessary and, if required, kept under supervision at 
the trial site or transferred to a hospital until all medical evaluation results have returned to an 
acceptable level.
Neurotoxicity
In dog toxicology studies, acute adverse neurological effects with tremor and movement 
disorder assessed as dyskinesia (paresis / rigidity) were observed at high exposures (see IB 
[c03536505-04]). One dog was euthanized due to overt neurotoxicity in 3-day escalation 
study at 90 mg/kg/day. In dose escalation study in dogs with assessment of neurotoxicity 
[n00245394], all clinical signs of neurotoxicity were reversible with cessation of dosing. No 
structural changes were observed on histopathology. Peripheral nerve conduction velocity 
and EEG were unchanged. No specific mechanism causing the neurological effects in dogs 
has been elucidated. Therefore, it has not been determined whether the neurological changes
are species specific; however, external expert review considered this is most likely a 
channelopathy specific to dog and not likely to occur in man (see IB).
Risk mitigation and monitoring: Subjects with relevant neurological disorder in the medical 
history are excluded from trial participation (see Section 3.3.3, criteria 7 and 22).
Neurological examinations as described in Section 5.2.5.1 will be performed at screening, 
and subjects with clinically relevant findings in the neurological examination will be 
excluded from study participation (see Section 3.3.3, criterion 1). If necessary (investigator 
decision), unscheduled neurological examinations may be performed at any time during the 
trial. Relevant findings in the neurological examination during the trial will be reported as 
AEs. If necessary, subjects may be sent for further, more specific evaluation and treatment to 
a local neurologist. 
Genotoxicity, reproductive and developmental toxicity
Genetic toxicology results by weight of evidence indicate that BI 894416 is not mutagenic or 
clastogenic. In the 2-week repeat dose range finding study in male rats [n00240179], 
degeneration of spermatids of the testes was observed at ≥400 mg/kg/day, which is 
considered a secondary effect, related to overt toxicity and morbidity. 
It is unknown whether BI 894416 or its metabolites are distributed into male semen. 
Theoretically there is therefore a risk for exposure of a study subject’s female partner who is 
a woman of child bearing potential (WOCBP) to subtherapeutic exposures of BI 894416 or 
its metabolites via male semen. Developmental and reproductive studies have not yet been 
conducted, therefore the effect of subtherapeutic concentrations of BI 894416 or its 
metabolites with regards to embryofetal risk has not been explored so far.


Boehringer Ingelheim
09 Sep 2019
BI Trial No.: 1371-0005
c26448055-04
Trial Protocol
Page 20 of 67
Proprietary confidential information © 2019 Boehringer Ingelheim International GmbH or one or more of its affiliated companies
001-MCS-40-106-RD-13 (6.0) / Saved on: 13 Jun 2018
Risk mitigation: In order to address the risk of exposure of a subject’s female WOCBP 
partner to BI 894416 or its metabolites via the subject’s seminal fluid, subjects need to use 
barrier contraception (condom) or abstinence (see Section 3.3.3).
Phototoxicity
Subjects will be advised to avoid direct exposure to sun and UV light during the entire study 
(see Section 4.2.2.2). Further protective measures would not be necessary given the low 
phototoxic potential of BI 894416.
Potential effects on QT interval
Preclinical studies suggested no proarrhythmic potential or cardiovascular liability with 
BI 894416. However, statistical results of first-in-man trial 1371-0001 showed a most-likely 
dose- and concentration-dependent increase of QTcF interval. At gMean Cmax of the 70 mg 
dose group, placebo- and baseline-corrected predicted mean QTcF increase was 5.9 ms 
(upper limit of the 90% CI was 10.5 ms). It is expected that plasma concentrations reached in 
current trial 1371-0005 are lower than the maximal plasma concentrations reached in trial 
1371-0001.
Risk mitigation: Subjects with cardiovascular disorders (Section 3.3.3, exclusion criterion 5), 
subjects who used drugs that cause QT/QTc prolongation (Section 3.3.3, exclusion criterion 
11), subjects that show a marked baseline prolongation of QT/QTc interval or any other 
relevant ECG finding at screening (Section 3.3.3, exclusion criterion 19), and subjects with a 
history of additional risk factors for Torsade de Pointes arrhythmia (Section 3.3.3, exclusion 
criterion 20) are excluded from trial participation. Moreover, subjects are in-house under 
close observation for 24 h following drug administration, and ECGs are done pre- and post-
dose at the time points given in the Flow Chart. Considering these risk-mitigating measures, 
the risks to subjects participating at trial 1371-0005 due to potential effects on QT interval are 
considered minimal.
1.4.3.2
Risks related to rifampicin
Rifampicin will be dosed for a limited period of time, i.e. 7 days during the present study at a 
clinical standard dose of 600 mg once daily. Multiple dose-administration of rifampicin is 
commonly used in drug-drug interaction trials involving healthy subjects because it allows 
investigating the impact of administration of a strong CYP3A inducer on the 
pharmacokinetics of co-administered (investigational) drugs.
In previous trials in healthy volunteers performed by us, administration of rifampicin for up 
to 12 days was of acceptable safety and tolerability [U09-1349-01, U10-1328-01, U12-1140-
01, U13-1478-01]. A typical side effect after administration of rifampicin to healthy subjects 
is reversible chromaturia. The colour of the urine may vary between orange, dark, orange, 
red, red-brown, and brown. Rarely, rifampicin can cause disturbances of blood count, such as 
leukopenia, neutropenia or thrombopenia. Frequently, mild hypersensitivity reactions can 
occur. Severe hypersensitivity reactions are rare or very rare. Frequently, gastrointestinal 


Boehringer Ingelheim
09 Sep 2019
BI Trial No.: 1371-0005
c26448055-04
Trial Protocol
Page 21 of 67
Proprietary confidential information © 2019 Boehringer Ingelheim International GmbH or one or more of its affiliated companies
001-MCS-40-106-RD-13 (6.0) / Saved on: 13 Jun 2018
symptoms are reported. Very frequent are increases of ALAT, ASAT, AP or gGT. 
Uncommon are icterus and hepatomegaly and acute hepatitis is very rare. A full listing of the 
reported side effects of rifampicin can be found in [R19-2541].
Risk mitigation: 
-
Safety and tolerability will be closely monitored during the trial, including regular 
assessment of adverse events and safety laboratory. 
-
Subjects will be instructed to report AEs spontaneously and will be asked at pre-
defined time points for AEs. In case of AEs in need of treatment, the investigator can 
authorise symptomatic therapy. In those cases, subjects will be treated as necessary 
and, if required, kept under supervision at the trial site or transferred to a hospital until 
all medical evaluation results have returned to an acceptable level. 
-
Individual treatment will be stopped if pre-specified criteria are met (see Section 
3.3.4.1). To account for the risk of rifampicin to very rarely cause acute hepatitis, an 
increase of ALAT and/or ASAT >2x ULN triggers stopping of individual treatment of 
a subject. 
-
A thorough screening examination will ensure that only suitable healthy subjects will 
enter the study. 
-
Only subjects with liver enzyme values that do not exceed the ULN will be included 
into the study (see Section 3.3.3, criterion 25). 
Considering these safety measures and taking into account the reported acceptable tolerability 
of rifampicin in healthy subjects, the planned administration of rifampicin does not represent 
an undue risk to healthy volunteers.
1.4.3.3
Risks related to combined administration of BI 894416 and rifampicin
Potential effects of BI 894416 on rifampicin pharmacokinetics and side effects
The last dose of rifampicin will be given 14 hours prior to BI 894416 in period 2. In this trial, 
no relevant effect of BI 894416 on rifampicin pharmacokinetics or side effects is expected.
Expected effects of rifampicin on BI 894416 pharmacokinetics and side effects
It is expected that BI 894416 plasma concentrations decrease when given following a 1-week 
treatment with rifampicin. This is not expected to increase the risk of side effects of 
BI 894416. 
1.4.3.4
Drug-induced liver injury
Although rare, a potential for drug-induced liver injury (DILI) is under constant surveillance 
by sponsors and regulators. Therefore, this trial requires timely detection, evaluation, and 
follow-up of laboratory alterations in selected liver laboratory parameters to ensure subjects´ 
safety; see also Section 5.2.6.1.4, adverse events of special interest.


Boehringer Ingelheim
09 Sep 2019
BI Trial No.: 1371-0005
c26448055-04
Trial Protocol
Page 22 of 67
Proprietary confidential information © 2019 Boehringer Ingelheim International GmbH or one or more of its affiliated companies
001-MCS-40-106-RD-13 (6.0) / Saved on: 13 Jun 2018
1.4.4
Overall assessment of benefit-risk ratio
BI 894416 is a highly specific SYK inhibitor that has been adequately characterised in pre-
clinical studies. The non-clinical safety package supports administration of BI 894416 for up 
to 4 weeks duration to men. 
Data of previous trial 1371-0001 indicate good safety and tolerability of single oral doses of 
BI 894416 at all dose levels, i.e. up to 70 mg. In addition, data from oral administration of 
three SYK inhibitors are available and provide additional information on safety and 
tolerability of this class of drug in man. Published data indicate acceptable safety and 
tolerability of these three SYK inhibitors in healthy volunteers (see IB [c03536505-04]).
BI 894416 plasma exposures in the current trial are expected to be within plasma exposure 
values that were observed in previous first-in-man trial 1371-0001 and that were associated 
with good safety and tolerability.
Rifampicin is a recommended inducer of CYP3A in clinical trials and has been used 
successfully and safely in previous clinical trials in healthy volunteers. The drug has a 
potential for hepatotoxicity, which is however accounted for by stringent exclusion criteria, 
liver enzyme measurement as part of safety laboratory examinations and stopping criteria for 
the individual subject.


Boehringer Ingelheim
09 Sep 2019
BI Trial No.: 1371-0005
c26448055-04
Trial Protocol
Page 23 of 67
Proprietary confidential information © 2019 Boehringer Ingelheim International GmbH or one or more of its affiliated companies
001-MCS-40-106-RD-13 (6.0) / Saved on: 13 Jun 2018
2.
TRIAL OBJECTIVES AND ENDPOINTS
2.1
MAIN OBJECTIVES, PRIMARY AND SECONDARY ENDPOINTS
2.1.1
Main objectives
The main objective of this trial is to investigate the effect of rifampicin on the 
pharmacokinetics of BI 894416.
2.1.2
Primary endpoints
The following pharmacokinetic parameters will be determined for BI 894416:

AUC0-∞(area under the concentration-time curve of the analyte in plasma over the 
time interval from 0 extrapolated to infinity)

Cmax (maximum measured concentration of the analyte in plasma)
2.1.3
Secondary endpoint
The following pharmacokinetic parameter will be determined for BI 894416:

AUC0-tz (area under the concentration-time curve of the analyte in plasma over the 
time interval from 0 to the last quantifiable data point)


Boehringer Ingelheim
09 Sep 2019
BI Trial No.: 1371-0005
c26448055-04
Trial Protocol
Page 24 of 67
Proprietary confidential information © 2019 Boehringer Ingelheim International GmbH or one or more of its affiliated companies
001-MCS-40-106-RD-13 (6.0) / Saved on: 13 Jun 2018


Boehringer Ingelheim
09 Sep 2019
BI Trial No.: 1371-0005
c26448055-04
Trial Protocol
Page 25 of 67
Proprietary confidential information © 2019 Boehringer Ingelheim International GmbH or one or more of its affiliated companies
001-MCS-40-106-RD-13 (6.0) / Saved on: 13 Jun 2018
3.
DESCRIPTION OF DESIGN AND TRIAL POPULATION
3.1
OVERALL TRIAL DESIGN AND PLAN
The study will be performed as an open-label, two-treatment, two-period, one-way crossover 
trial in healthy male subjects in order to compare the test treatment (T) to the reference 
treatment (R). The treatments will be one oral single dose of 50 mg BI 894416 as tablet 
formulation (tablet strength: 25 mg) following 7 days of pre-treatment with 600 mg 
rifampicin q.d. as tablet formulation (tablet strength: 600 mg) (T) and one oral single dose of 
50 mg BI 894416 as tablet formulation (tablet strength: 25 mg) given alone (R). In both 
treatments, BI 894416 is administered in the fasting state. In the first treatment period (Period 
1, Visit 2), all subjects are planned to undergo treatment R, and in the second treatment 
period (Period 2, Visit 3), all subjects are planned to undergo treatment T. For details, refer to 
Section 4.1.
There will be a washout period of at least 10 days between the administrations of BI 894416.
Based on the good safety and tolerability of BI 894416 in trial 1371-0001, the acceptable 
safety and tolerability of rifampicin in healthy volunteers and the fact that a decrease of 
BI 894416 exposure is expected when given together with the CYP and P-glycoprotein 
inducer rifampicin, it is acceptable to treat all subjects entered in this trial in a single cohort, 
i.e. with Day 1 of each treatment period on the same calendar day.
An overview of all relevant trial activities is provided in the Flow Chart. For visit schedule 
and details of trial procedures at selected visits, refer to Sections 6.1 and 6.2, respectively.
3.2
DISCUSSION OF TRIAL DESIGN, INCLUDING THE CHOICE OF 
CONTROL GROUP
For relative bioavailability trials, the crossover design is preferred because of its efficiency: 
since each subject serves as his own control, the comparison between treatments is based on 
an intra-subject comparison, thus removing inter-subject variability from the comparison 
between treatments [R94-1529].
Considering the potentially long-lasting induction effect of rifampicin with regards to CYP
enzymes, and in order to avoid carry-over effects of rifampicin-induced induction, a one-way 
crossover design was selected, with administration of rifampicin in the second treatment 
period only. This design is not expected to lead to systematic errors in the estimation of the 
treatment effects since nonspecific time effects are unlikely due to the short trial duration. 
Due to short half-life of BI 894416 and the sustained induction effect of rifampicin, 
rifampicin is not administered on Day 1 of period 2. 
The open-label treatment is not expected to bias results, since the primary and secondary 
study endpoints are derived from measurement of plasma concentrations of the analyte.
These endpoints are not expected to be affected by knowledge of treatment.


Boehringer Ingelheim
09 Sep 2019
BI Trial No.: 1371-0005
c26448055-04
Trial Protocol
Page 26 of 67
Proprietary confidential information © 2019 Boehringer Ingelheim International GmbH or one or more of its affiliated companies
001-MCS-40-106-RD-13 (6.0) / Saved on: 13 Jun 2018
3.3
SELECTION OF TRIAL POPULATION
It is planned that 16 healthy male subjects will enter the study. They will be recruited from 
the volunteers' pool of the trial site.
Only male subjects will be included in the study because no data on reproductive toxicology 
are available at this time and because, until availability of data from the 26-week Tg.rasH2 
carcinogenicity study, study populations are restricted to male volunteers or patients (see IB 
[c03536505-04]).
A log of all subjects enrolled into the trial (i.e. who have signed informed consent) will be 
maintained in the ISF irrespective of whether they have been treated with investigational drug 
or not.
3.3.1
Main diagnosis for trial entry
The study will be performed in healthy subjects.
3.3.2
Inclusion criteria
Subjects will only be included in the trial if they meet the following criteria:
1. Healthy male subjects according to the assessment of the investigator, as based on a 
complete medical history including a physical examination, vital signs (BP, PR), 12-lead 
ECG, and clinical laboratory tests 
2. Age of 18 to 50 years (inclusive) 
3. BMI of 18.5 to 29.9 kg/m2 (inclusive) 
4. Signed and dated written informed consent prior to admission to the study, in accordance 
with GCP and local legislation
3.3.3
Exclusion criteria
Subjects will not be allowed to participate, if any of the following general criteria apply:
1. Any finding in the medical examination (including BP, PR or ECG and including the 
neurological examination) deviating from normal and assessed as clinically relevant by 
the investigator
2. Repeated measurement of systolic blood pressure outside the range of 90 to 140 mmHg, 
diastolic blood pressure outside the range of 50 to 90 mmHg, or pulse rate outside the 
range of 45 to 90 bpm
3. Any laboratory value outside the reference range that the investigator considers to be of 
clinical relevance
4. Any evidence of a concomitant disease assessed as clinically relevant by the investigator
5. Gastrointestinal, hepatic, renal, respiratory, cardiovascular, metabolic, immunological or 
hormonal disorders
6. Cholecystectomy or other surgery of the gastrointestinal tract that could interfere with the 
pharmacokinetics of the trial medication (except appendectomy or simple hernia repair)


Boehringer Ingelheim
09 Sep 2019
BI Trial No.: 1371-0005
c26448055-04
Trial Protocol
Page 27 of 67
Proprietary confidential information © 2019 Boehringer Ingelheim International GmbH or one or more of its affiliated companies
001-MCS-40-106-RD-13 (6.0) / Saved on: 13 Jun 2018
7. Diseases of the central nervous system (including but not limited to any kind of seizures 
or stroke), and other relevant neurological or psychiatric disorders 
8. History of relevant orthostatic hypotension, fainting spells, or blackouts
9. Chronic or relevant acute infections
10. History of relevant allergy or hypersensitivity (including allergy to the trial medication or 
its excipients) 
11. Use of drugs within 30 days of planned administration of trial medication that might 
reasonably influence the results of the trial (including drugs that cause QT/QTc interval
prolongation)
12. Intake of an investigational drug in another clinical trial within 60 days of planned  
administration of investigational drug in the current trial, or concurrent participation in 
another clinical trial in which investigational drug is administered
13. Smoker (unless the subject quit smoking for at least 3 months prior to first planned 
administration of trial medication)
14. Alcohol abuse (consumption of more than 24 g per day)
15. Drug abuse or positive drug screening
16. Blood donation of more than 100 mL within 30 days of planned administration of trial 
medication or intended blood donation during the trial
17. Intention to perform excessive physical activities within one week prior to the 
administration of trial medication or during the trial
18. Inability to comply with the dietary regimen of the trial site
19. A marked baseline prolongation of QT/QTc interval (such as QTc intervals that are 
repeatedly greater than 450 ms) or any other relevant ECG finding at screening
20. A history of additional risk factors for Torsade de Pointes (such as heart failure, 
hypokalaemia, or family history of Long QT Syndrome)
21. Subject is assessed as unsuitable for inclusion by the investigator, for instance, because 
the subject is not considered able to understand and comply with study requirements, or 
has a condition that would not allow safe participation in the study 
In addition, the following trial-specific exclusion criteria apply:
22. History of relevant neurological disorder affecting the peripheral or central nervous 
system (this includes, but is not limited to: stroke, epilepsy, inflammatory or atrophic 
diseases affecting the nervous system, cluster headache or any cancer of the nervous 
system). Febrile seizures in childhood or adolescence, recovered carpal tunnel syndrome, 
recovered uncomplicated meningitis, recovered herpes zoster, tension headache, 
occasional benign tics (e.g. due to stress) or minor par- or dysesthesia (e.g. as a side effect 
of prior blood withdrawal) do not constitute a history of relevant neurological disorder.
23. History of immunological disease except allergy not relevant to the trial (such as mild hay 
fever or dust mite allergy) and except asthma in childhood or adolescence
24. History of cancer (other than successfully treated basal cell carcinoma)
25. Liver enzymes (ALT, AST, gGT, AP) above upper limit of normal at the screening 
examination


Boehringer Ingelheim
09 Sep 2019
BI Trial No.: 1371-0005
c26448055-04
Trial Protocol
Page 28 of 67
Proprietary confidential information © 2019 Boehringer Ingelheim International GmbH or one or more of its affiliated companies
001-MCS-40-106-RD-13 (6.0) / Saved on: 13 Jun 2018
26. Within 10 days prior to administration of trial medication, use of any drug that could 
reasonably inhibit platelet aggregation or coagulation (e.g., acetylsalicylic acid)
27. Male subjects with WOCBP partner who are unwilling to use male contraception 
(condom or sexual abstinence) from time point of first administration of trial medication 
until 30 days after the last administration of trial medication
For study restrictions, refer to Section 4.2.2.
3.3.4
Withdrawal of subjects from treatment or assessments
Subjects may discontinue trial treatment or withdraw consent to trial participation as a whole 
(‘withdrawal of consent’) with very different implications; please see Sections 3.3.4.1 and 
3.3.4.2 below.
If a subject is removed from or withdraws from the trial prior to the first administration of 
trial medication, the data of this subject will not be entered in the case report form (CRF) and 
will not be reported in the clinical trial report (CTR). If a subject is removed from or 
withdraws from the trial after the first administration of trial medication, this will be 
documented and the reason for discontinuation must be recorded in the CRF; in addition, the 
data will be included in the CRF and will be reported in the CTR. At the time of 
discontinuation, a complete end of trial examination will be performed, if possible, and the 
information will be recorded in the CRF. 
3.3.4.1
Discontinuation of trial treatment
An individual subject will discontinue trial treatment if:
1. The subject wants to discontinue trial treatment, without the need to justify the decision
2. The subject has repeatedly shown to be non-compliant with important trial procedures 
and, in the opinion of both, the investigator and sponsor representative, is not willing or 
able to adhere to the trial requirements in the future.
3. The subject needs to take concomitant medication that interferes with the investigational 
medicinal product or other trial treatment
4. The subject can no longer receive trial treatment for medical reasons (such as surgery, 
adverse events [AEs], or diseases)
5. The subject has an elevation of AST and/or ALT ≥2-fold ULN and/or needs to be 
followed up according to the DILI checklist provided in the ISF
6. The subject experiences a drug-related AE of severe intensity or a serious AE
In addition to these criteria, the investigator may discontinue subjects at any time based on 
his or her clinical judgment.
Even if the trial treatment is discontinued, the subject remains in the trial and, given his
agreement, will undergo the procedures for early treatment discontinuation and follow up as 
outlined in the Flow Chart and Section 6.2.3.


Boehringer Ingelheim
09 Sep 2019
BI Trial No.: 1371-0005
c26448055-04
Trial Protocol
Page 29 of 67
Proprietary confidential information © 2019 Boehringer Ingelheim International GmbH or one or more of its affiliated companies
001-MCS-40-106-RD-13 (6.0) / Saved on: 13 Jun 2018
3.3.4.2
Withdrawal of consent to trial participation
Subjects may withdraw their consent to trial participation at any time without the need to 
justify the decision. If a subject wants to withdraw consent, the investigator should be 
involved in the discussion with the subject and explain the difference between trial treatment 
discontinuation and withdrawal of consent to trial participation, as well as explain the options 
for continued follow up after trial treatment discontinuation, please see Section 3.3.4.1 above
3.3.4.3
Discontinuation of the trial by the sponsor
Boehringer Ingelheim reserves the right to discontinue the trial at any time for any of the 
following reasons:
1. Failure to meet expected enrolment goals overall or at a particular trial site
2. New toxicological findings, serious adverse events, or any safety information invalidating
the earlier positive benefit-risk-assessment. More specifically, the trial will be terminated 
if more than 50% of the subjects have drug-related and clinically relevant adverse events 
of moderate or severe intensity, or if at least 1 drug-related serious adverse event is 
reported
3. Violation of GCP or the CTP impairing the appropriate conduct of the trial-
4. The sponsor decides to discontinue the further development of the investigational product
3.3.5
Replacement of subjects
In case more than 4 subjects do not complete the trial, the Clinical Trial Leader together with 
the Trial Pharmacokineticist and the Trial Statistician are to decide, if and how many subjects 
will be replaced. A replacement subject will be assigned a unique trial subject number, and 
will be assigned to the same treatment as the subject 
 replaces.


Boehringer Ingelheim
09 Sep 2019
BI Trial No.: 1371-0005
c26448055-04
Trial Protocol
Page 30 of 67
Proprietary confidential information © 2019 Boehringer Ingelheim International GmbH or one or more of its affiliated companies
001-MCS-40-106-RD-13 (6.0) / Saved on: 13 Jun 2018
4.
TREATMENTS
4.1
INVESTIGATIONAL TREATMENTS
The investigational product BI 894416 as tablet formulation has been manufactured by BI
Pharma GmbH & Co. KG. Rifampicin tablets will be obtained from a public pharmacy by the 
trial site. 
4.1.1
Identity of the Investigational Medicinal Products
The characteristics of the test product are given below:
Test product 1:
Substance:
BI 894416
Pharmaceutical formulation:
Tablet
Source:
BI Pharma GmbH & Co. KG, Germany
Unit strength:
25 mg
Posology:
2-0-0
Route of administration:
oral
Duration of use:
1 day (in treatment periods 1 and 2)
Test product 2:
Name:
Eremfat® 600 mg
Substance:
Rifampicin
Pharmaceutical formulation:
Film-coated tablet
Source:
Public pharmacy (obtained by the site)
Holder of marketing authorization: 
Unit strength:
600 mg
Posology:
0-0-1
Route of administration:
oral
Duration of use:
7 days (Days -7 to -1 in treatment period 2) 
4.1.2
Selection of doses in the trial
Perpetrator (rifampicin)
Rifampicin given at a dosage of 600 mg once daily reflects standard clinical doses and is 
considered sufficient to yield significant CYP3A induction. 


Boehringer Ingelheim
09 Sep 2019
BI Trial No.: 1371-0005
c26448055-04
Trial Protocol
Page 31 of 67
Proprietary confidential information © 2019 Boehringer Ingelheim International GmbH or one or more of its affiliated companies
001-MCS-40-106-RD-13 (6.0) / Saved on: 13 Jun 2018
Victim (BI 894416) 
Based on in vitro data, CYP3A is major responsible enzyme for metabolism of BI 894416. 
Additionally, BI 894416 was determined to be a substrate of CYP1A1, an extrahepatic 
enzyme expressed in tissues such as lung and small intestine. Concomitant administration of 
BI 894416 with the strong CYP3A inducer rifampicin may result in reduction of BI 894416 
plasma concentrations. It is not expected that plasma concentrations of BI 894416 could 
increase when given together with rifampicin in this trial, in particular because of the interval 
of 14 hours between last administration of rifampicin on Day -1 of period 2 and the following 
administration of BI 894416 on Day 1 of period 2. This time interval of 14 hours makes any 
inhibitory effects of rifampicin that could potentially increase plasma concentrations of 
BI 894416, such as inhibition of intestinal P-glycoprotein, unlikely.
For the current trial, a dose of 50 mg BI 894416 is selected. 
 
 see IB c03536505-04), and it is in the range of doses that were given in 
first-in-man trial 1371-0001 to healthy volunteers and that were associated with good safety 
and tolerability. 
In the SRD part of trial 1371-0001, single oral doses of 3 to 70 mg BI 894416 were given as 
oral solution formulation under fasting conditions, and available data indicate that, at all 
doses tested, BI 894416 administration was safe and well tolerated. In the 70 mg dose group 
of trial 1371-0001, gMean values for Cmax and AUC0-24 of 2130 nM and 11100 nM*h, 
respectively, were reached [c03536505-04]. In the 54 mg dose group of trial 1371-0001, 
gMean values for Cmax and AUC0-24 of 1240 nM and 6940 nM*h, respectively, were reached 
[c03536505-04]. I.e., the ratios of gMean plasma exposure parameters at 70 mg and at 54 mg 
were approximately 1.7 (Cmax) and 1.6 (AUC0-24). These ratios are assessed to be sufficient as 
safety margins for the current trial, in particular as a decrease of BI 894416 plasma 
concentrations is expected when given with rifampicin. 
4.1.3
Method of assigning subjects to treatment groups
There is only one treatment sequence investigated in this trial, and each subject will be 
allocated to the same treatment sequence (R-T). The subjects will be allocated to a study 
subject number by the method‘first come - first served’prior to first administration of trial
medication in the morning of Day 1 of Visit 2. Reference and test treatments will be 
administered in the sequence specified in the Flow Chart. 
Once a subject number has been assigned, it cannot be reassigned to any other subject.
The application of single BI 894416 doses of up to 70 mg (1371-0001) was well tolerated. 
For details on these results, refer to Sections 1.4.3 and 4.1.2 of the protocol. 
Two possible interactions are known for rifampicin: (1) it causes induction of CYP3A4 and 
would therefore lead to a decreased BI 894416 exposure, and (2) it can interact with drug 
transporters which might lead to an increasde BI 894416 exposure. By applying rifampicin in 
the evening and dosing BI 894416 at the next morning (refer to flow chart), an increase of BI 
894416 exposure is not expected. Therefore, this dose regime is used in this study and an 


Boehringer Ingelheim
09 Sep 2019
BI Trial No.: 1371-0005
c26448055-04
Trial Protocol
Page 32 of 67
Proprietary confidential information © 2019 Boehringer Ingelheim International GmbH or one or more of its affiliated companies
001-MCS-40-106-RD-13 (6.0) / Saved on: 13 Jun 2018
unexpected increase of BI 894416 exposure, beyond the exposure tested in the preceding 
study 1371-0001, is unlikely. 
Thus, there should be no undue risk for a subject participating in the this study. In addition, it 
is considered an acceptable option that an entire cohort of up to 16 subjects may be dosed on 
one day, due to (1) the seen good tolerability of up to 70 mg in the SRD study and (2) the 
application of 50 mg (below the highest tested dose in study 1371-0001) with an expected 
lower exposure after CYP 3A4 induction.
4.1.4
Drug assignment and administration of doses for each subject
This trial is a one-way crossover study. All subjects will receive the 2 treatments in fixed
order. The treatments to be evaluated are outlined in Table 4.1.4: 1 below. 
Table 4.1.4: 1
Dosage and treatment schedule
Treatment 
period
Treatment
Substance
Formulation
Unit 
strength
Dosage
Total dose
1
R (Reference)
BI 894416
Tablet
25 mg
2 tablets as single dose
on Day 1
50 mg
2
T (Test)
Rifampicin
BI 894416
Film-coated 
tablet
Tablet
600 mg
25 mg
1 tablet q.d on Days -7 
to -1
2 tablets as single dose
on Day 1
4200 mg
50 mg
Administration of BI 894416 will be performed after subjects have fasted overnight; fasting 
is to start no later than 10 h before the scheduled dosing. 
For administrations of rifampicin, subjects are advised to fast for at least 2 hours before and 
at least 30 minutes after drug administrations.
The investigator (or authorised designee) will administer the trial medication as an oral dose 
together with about 240 mL of water to subjects who are in a standing position. For drug 
administration, the so-called four-eye principle (two-person rule) should be applied. For this, 
one authorised employee of the trial site should witness the administration of trial medication, 
and – if applicable – its preparation (e.g. reconstitution), if correct dosage cannot be ensured 
otherwise.
For restrictions with regard to diet, see Section 4.2.2.2.
Subjects will be kept under close medical surveillance until 24 h after BI 894416
administration. During the first 4 h after BI 894416 administration, subjects are not allowed 
to lie down (i.e. no declination of the upper body of more than 45 degrees from upright 
posture).
The first rifampicin administration will be followed by a 2-hour post-administration in-house 
observation period.
The administrations of BI 894416 will be separated by a wash-out phase of at least 10 days.


Boehringer Ingelheim
09 Sep 2019
BI Trial No.: 1371-0005
c26448055-04
Trial Protocol
Page 33 of 67
Proprietary confidential information © 2019 Boehringer Ingelheim International GmbH or one or more of its affiliated companies
001-MCS-40-106-RD-13 (6.0) / Saved on: 13 Jun 2018
4.1.5
Blinding and procedures for unblinding
This Phase I trial will be handled in an open fashion throughout (that is, during the conduct,
including data cleaning and preparation of the analysis). This is considered acceptable 
because the potential for bias seems to be low and does not outweigh practical considerations.
Emergency envelopes will not be provided, because the dose of trial medication is known to 
investigators and subjects.
4.1.6
Packaging, labelling, and re-supply
BI 894416 tablets
BI 894416 tablets will be provided by BI. They will be packaged and labelled in accordance 
with local law and the principles of Good Manufacturing Practice. 
For details of packing and the description of the label, refer to the ISF.
The telephone number of the sponsor and the name, address and telephone number of the trial 
site are provided in the subject information form. The EudraCT number is indicated on the 
title page of this protocol as well as on the subject information and informed consent forms. 
No re-supply is planned.
Rifampicin tablets
Rifampicin tablets will be obtained by the clinical trial site from a public pharmacy. The drug 
will be dispensed out of the original, unmodified packages.
4.1.7
Storage conditions
Drug supplies will be kept in their original packaging and in a secure limited access storage 
area in accordance with the recommended (labelled) storage conditions. If necessary, a 
temperature log must be maintained to make certain that the drug supplies are stored at the 
correct temperature. If the storage conditions are found to be outside the specified range, the 
clinical trial manager (as provided in the list of contacts) is to be contacted immediately.
4.1.8
Drug accountability
The investigator or designee will receive the investigational drugs delivered from the sponsor
following requirements are fulfilled:

Approval of the clinical trial protocol by the IRB / ethics committee

Approval/notification of the regulatory authority,  e.g. competent authority

Availability of the curriculum vitae of the Principal Investigator

Availability of a signed and dated clinical trial protocol  
Only authorised personnel documented in the form 'Trial Staff List' may dispense medication 
to trial subjects. The trial medication must be administered in the manner specified in the 
CTP.


Boehringer Ingelheim
09 Sep 2019
BI Trial No.: 1371-0005
c26448055-04
Trial Protocol
Page 34 of 67
Proprietary confidential information © 2019 Boehringer Ingelheim International GmbH or one or more of its affiliated companies
001-MCS-40-106-RD-13 (6.0) / Saved on: 13 Jun 2018
The investigator or designee must maintain records of the product’s delivery to the trial site, 
the inventory at the site, the use by each subject, and the disposal of unused products.These 
records will include dates, quantities, batch / serial numbers, expiry ('use-by') dates, and the 
unique code numbers assigned to the investigational medicinal product and trial subjects. The 
investigator or designee will maintain records that document adequately that the subjects 
were provided the doses specified by the CTP and reconcile all investigational medicinal 
products received from the sponsor. At the time of disposal of remaining trial medication, the 
investigator or designee must verify that no remaining supplies are in the investigator’s 
possession.
All unused medication will be disposed of locally by the trial site upon written authorisation 
of the clinical trial leader. Receipt, usage and disposal of trial medication must be 
documented on the appropriate forms. Account must be given for any discrepancies.
4.2
OTHER TREATMENTS, EMERGENCY  PROCEDURES,
RESTRICTIONS
4.2.1
Other treatments and emergency procedures
There are no special emergency procedures to be followed. No additional treatment is 
planned. However, if adverse events require treatment, the investigator can authorise 
symptomatic therapy. In those cases, subjects will be treated as necessary and, if required, 
kept under supervision at the trial site or transferred to a hospital until all results of medical 
evaluations are acceptable.
4.2.2
Restrictions
4.2.2.1
Restrictions regarding concomitant treatment
In principle, no concomitant therapy is allowed. All concomitant or rescue therapies will be 
recorded (including time of intake on study days) on the appropriate pages of the CRF.
Acetylsalicylic acid or other drugs that may inhibit platelet aggregation or coagulation should 
be avoided during the entire study. 
Paracetamol, diclofenac or other drugs with relevant hepatotoxicity should be avoided during 
the entire study.
Known inhibitors/inducers of CYP3A and P-glycoprotein should be avoided during the entire 
study.
If needed, ibuprofen may be given to treat adverse events, e.g. headache.
4.2.2.2
Restrictions on diet and life style
Poppy-seeds containing foods should not be consumed starting 3 days before the first drug 
administration in treatment period 1 until after the last PK sample in period 2 in order to 
avoid false-positive results in the drug screen.


Boehringer Ingelheim
09 Sep 2019
BI Trial No.: 1371-0005
c26448055-04
Trial Protocol
Page 35 of 67
Proprietary confidential information © 2019 Boehringer Ingelheim International GmbH or one or more of its affiliated companies
001-MCS-40-106-RD-13 (6.0) / Saved on: 13 Jun 2018
While admitted to the trial site, the subjects will be instructed not to consume any foods or 
drinks other than those provided by the staff. Standardised meals will be served at the times
indicated in the Flow Chart.
No food is allowed for at least 10 h before and 4 h after intake of BI 894416. 
Subjects will be advised to not consume any food within at least 2 h before and 30 min after 
intake of rifampicin.
On Day 1 of each treatment period, from 1 h before drug intake until lunch, fluid intake is 
restricted to the water administered with the drug, and an additional 240 mL of water at 2 h 
and 4 h post-dose (mandatory for all subjects). From lunch until 24 h post-dose, total fluid 
intake is restricted to 3000 mL.
Grapefruits, Seville oranges (sour or bitter oranges) and their juices, and dietary supplements 
and products containing St. John's wort (Hypericum perforatum) are not permitted from 7 
days before the first administration of trial medication until after the last PK sample in the 
second treatment period is collected.
Alcoholic beverages are not permitted from 2 days before the first administration of trial 
medication in period 1 until after the last PK sample in period 2 is collected.
Smoking is not allowed during the trial.
Barbecued meat and broccoli should be avoided during the trial.
Methylxanthine-containing drinks or foods (such as coffee, tea, cola, energy drinks, or 
chocolate) are not allowed from 10 h before until 24 h after each administration of 
BI 894416.
Excessive physical activity (such as competitive sport) should be avoided from 7 days before 
the first administration of trial medication until the end of trial examination.
Direct exposure to the sun or exposure to solarium radiation should be avoided during the 
entire study.
4.3
TREATMENT COMPLIANCE
Compliance will be assured by administration of all trial medication in the study centre under 
supervision of the investigating physician or a designee. The measured plasma concentrations 
of trial medication will provide additional confirmation of compliance.
Subjects who are non-compliant (for instance, who do not appear for scheduled visits or 
violate trial restrictions) may be removed from the trial and the CRF will be completed 
accordingly (for further procedures, please see Section 3.3.4.1).


Boehringer Ingelheim
09 Sep 2019
BI Trial No.: 1371-0005
c26448055-04
Trial Protocol
Page 36 of 67
Proprietary confidential information © 2019 Boehringer Ingelheim International GmbH or one or more of its affiliated companies
001-MCS-40-106-RD-13 (6.0) / Saved on: 13 Jun 2018
5.
ASSESSMENTS
5.1
ASSESSMENT OF EFFICACY
Not applicable.
5.2
ASSESSMENT OF SAFETY
5.2.1
Physical examination
At screening, the medical examination will include demographics, height and body weight, 
smoking and alcohol history (alcohol history not mandatory to be entered into CRF or to be 
reported), relevant medical history and concomitant therapy, review of inclusion and 
exclusion criteria, review of vital signs (BP, PR), 12-lead ECG, laboratory tests, a physical 
examination, and a neurological examination. At the end of trial examination, it will include 
review of vital signs, 12-lead ECG, laboratory tests, a physical examination, and a 
neurological examination.
5.2.2
Vital signs
Systolic and diastolic blood pressures (BP) as well as pulse rate (PR) will be measured by a 
blood pressure monitor (Dinamap, 
) at the times 
indicated in the Flow Chart, after subjects have rested for at least 5 min in a supine position. 
All recordings should be made using the same type of blood pressure recording instrument on 
the same arm, if possible.
5.2.3
Safety laboratory parameters
For the assessment of laboratory parameters, blood and urine samples will be collected by the 
trial site at the times indicated in the Flow Chart. For safety laboratory parameter sets A and 
B subjects should be fasted for at least 10 h. For safety laboratory parameter set C, fasting is 
not required. For retests, at the discretion of the investigator or designee, overnight fasting is 
not required. 
The parameters that will be determined are listed in Tables 5.2.3: 1 and 5.2.3: 2. Reference 
ranges will be provided in the ISF, Section 10. 
Manual differential white blood cell count or urine sediment examinations will only be 
performed if there is an abnormality in the automatic blood cell count or in the urinalysis, 
respectively.


Boehringer Ingelheim
09 Sep 2019
BI Trial No.: 1371-0005
c26448055-04
Trial Protocol
Page 37 of 67
Proprietary confidential information © 2019 Boehringer Ingelheim International GmbH or one or more of its affiliated companies
001-MCS-40-106-RD-13 (6.0) / Saved on: 13 Jun 2018
Table 5.2.3: 1
Routine laboratory tests
Functional lab group
BI test name [comment/abbreviation]
A1
B1
C1
Haematology
Haematocrit
Haemoglobin
Red Blood Cell Count/Erythrocytes 
White Blood Cells/Leucocytes
Platelet Count/Thrombocytes (quant)
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
Automatic WBC 
differential, relative 
Neutrophils/Leukocytes; Eosinophils/Leukocytes; Basophils/ 
Leukocytes; Monocytes/Leukocytes; 
Lymphocytes/Leukocytes 
X
X
X
Automatic WBC 
differential, absolute 
Neutrophil, absol.; Eosinophils, absol.; Basophils, absol.; 
Monocytes, absol.; Lymphocytes, absol.
X
X
X
Manual differential 
WBC (if automatic
differential WBC is 
abnormal and 
clinically relevant in 
the opinion of the 
investigator)
Neut. Poly (segs); Neut. Poly (segs), absol.; Neutrophils 
Bands; Neutrophils Bands, absol.; Eosinophils/Leukocytes; 
Eosinophils, absol.; Basophils/ Leukocytes; Basophils, absol.; 
Monocytes/ Leukocytes; Monocytes, absol.; 
Lymphocytes/Leukocytes; Lymphocytes, absol.
Coagulation
Activated Partial Thromboplastin Time 
Prothrombin time – INR (International Normalization Ratio)
X
X
X
X
--
--
Enzymes
AST [Aspartate transaminase] /GOT, SGOT 
ALT [Alanine transaminase] /GPT, SGPT
Alkaline Phosphatase
Gamma-Glutamyl Transferase 
X
X
X
X
X
X
X
X
X
X
X
X
Hormones
Thyroid Stimulating Hormone
X
--
--
Substrates
Glucose (Plasma)
Creatinine 
Bilirubin, Total 
Bilirubin, Direct
Protein, Total
C-Reactive Protein (Quant)  
X
X
X
X
X
X
X
X
X
X
X
X
--
--
X
X
--
--
Electrolytes
Sodium
Potassium
X
X
X
X
--
--
Urinalysis1 (Stix)
Urine Nitrite (qual)
Urine Protein (qual)
Urine Glucose (qual)
Urine Ketone (qual)
Urobilinogen (qual)
Urine Bilirubin (qual)
Urine Haemoglobin (qual)
Urine WBC/Leucocytes (qual)
Urine pH
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
--
--
--
--
--
--
--
--
--
Urine sediment 
(microscopic 
examination if 
haemoglobin, 
leukocytes nitrite or 
protein are abnormal 
in urine)
Only positive findings will be reported (for instance, the 
presence of sediment bacteria, casts in sediment, squamous 
epithelial cells, erythrocytes, leukocytes)
1 A, B, and C are different sets of laboratory values. The Flow Chart details at which time point which set is to 
be investigated.


Boehringer Ingelheim
09 Sep 2019
BI Trial No.: 1371-0005
c26448055-04
Trial Protocol
Page 38 of 67
Proprietary confidential information © 2019 Boehringer Ingelheim International GmbH or one or more of its affiliated companies
001-MCS-40-106-RD-13 (6.0) / Saved on: 13 Jun 2018
The tests listed in Table 5.2.3: 2 are exclusionary laboratory tests that may be repeated as 
required. The results will not be entered in the CRF/database and will not be reported in the 
CTR. Except for drug screening, it is planned to perform these tests during screening only. 
Drug screening will be performed at screening and prior to each treatment period.
Table 5.2.3: 2
Exclusionary laboratory tests
Functional lab group
Test name 
Drug screening (urine)
Amphetamine/MDA
Barbiturates
Benzodiazepine
Cannabis
Cocaine 
Methadone
Methamphetamines/MDMA/XTC
Opiates 
Phencyclidine
Tricyclic antidepressants
Cotinine test (urine)
Cotinine
Infectious serology (blood)
Hepatitis B surface antigen (qualitative)
Hepatitis B core antibody (qualitative)
Hepatitis C antibodies (qualitative)
HIV-1 and HIV-2 antibody (qualitative)
To encourage compliance with alcoholic restrictions, a breath alcohol test (e.g. Alcotest®
7410, 
) will be performed prior to each treatment period, and 
may be repeated at any time during the study at the discretion of an investigator or designee. 
The results will not be included in the CTR.
The laboratory tests listed in Tables 5.2.3: 1 and 5.2.3: 2 will be performed at
 with the 
exception of drug screening tests and the Cotinine test at screening. These tests will be 
performed at the trial site using Multidrogen Pipettiertest (
, 
), or comparable test systems.
Laboratory data will be transmitted electronically from the laboratory to the trial site.
5.2.4
Electrocardiogram
Twelve-lead ECGs (I, II, III, aVR, aVL, aVF, V1 - V6) will be recorded using a 
computerised electrocardiograph (
 
) at the times provided in the Flow Chart. 
To achieve a stable heart rate at rest and to assure high quality recordings, the site personnel 
will be instructed to assure a relaxed and quiet environment, so that all subjects are at 
complete rest.


Boehringer Ingelheim
09 Sep 2019
BI Trial No.: 1371-0005
c26448055-04
Trial Protocol
Page 39 of 67
Proprietary confidential information © 2019 Boehringer Ingelheim International GmbH or one or more of its affiliated companies
001-MCS-40-106-RD-13 (6.0) / Saved on: 13 Jun 2018
All ECGs will be recorded for a 10 sec duration after subjects have rested for at least 5 min in 
a supine position. ECG assessment will always precede all other study procedures scheduled 
for the same time to avoid compromising ECG quality. 
All ECGs will be stored electronically on the Muse CV Cardiology System (
 
). Electrode placement will be performed according to the 
method of Wilson, Goldberger and Einthoven modified by Mason and Likar (hips and 
shoulders instead of ankles and wrists). 
All locally printed ECGs will be evaluated by the investigator or a designee. Abnormal 
findings will be reported as AEs (during the trial) or baseline conditions (at screening) if 
assessed to be clinically relevant by the investigator. Any ECG abnormalities will be 
carefully monitored and, if necessary, the subject will be removed from the trial and will 
receive the appropriate medical treatment. 
ECGs may be repeated for quality reasons (for instance, due to alternating current artefacts, 
muscle movements, or electrode dislocation) and the repeated ECG will be used for analysis. 
Additional (unscheduled) ECGs may be collected by the investigator for safety reasons. 
5.2.5
Other safety parameters
5.2.5.1
Neurological examination
At Screening and at EoTrial examination, a physical neurological examination will be 
performed. Upon investigator judgment, additional neurological examinations may be added 
at any time during the trial, for individual subjects or for the whole treatment group.
The neurological examination will include the following assessments:
-
Eye movement
-
Pupil size and pupil reactivity
-
Reflexes 
-
Assessment of muscle strength
-
Gait
-
Romberg test
-
Tremor
-
Point-to-point movements
-
Sensitivity
Documentation, Assessment, and Reporting
Results will be documented in source data at the clinical trial site and assessed for clinical 
relevance by an investigator, deputy investigator or sub-investigator. Clinically relevant 
findings of the neurological examination will be reported as Adverse Events (during the trial) 
or as baseline conditions (at screening). Case narratives may be written if necessary.


Boehringer Ingelheim
09 Sep 2019
BI Trial No.: 1371-0005
c26448055-04
Trial Protocol
Page 40 of 67
Proprietary confidential information © 2019 Boehringer Ingelheim International GmbH or one or more of its affiliated companies
001-MCS-40-106-RD-13 (6.0) / Saved on: 13 Jun 2018
5.2.6
Assessment of adverse events
5.2.6.1
Definitions of adverse events
Adverse event
5.2.6.1.1
An adverse event (AE) is defined as any untoward medical occurrence in a patient or clinical 
investigation subject administered a medicinal product and which does not necessarily have 
to have a causal relationship with this treatment.
An AE can therefore be any unfavourable and unintended sign (including an abnormal 
laboratory finding), symptom, or disease temporally associated with the use of a medicinal 
product, whether or not considered related to the medicinal product.
The following should also be recorded as an AE in the CRF and BI SAE form (if applicable):

Worsening of the underlying disease or of other pre-existing conditions 

Changes in vital signs, ECG, physical examination, and laboratory test results, if they 
are judged clinically relevant by the investigator
If such abnormalities already pre-exist prior to trial inclusion, they will be considered as 
baseline conditions and should be collected in the eCRF only.
Serious adverse event
5.2.6.1.2
A serious adverse event (SAE) is defined as any AE which fulfils at least one of the 
following criteria:

Results in death 

Is life-threatening, which refers to an event in which the patient was at risk of death 
at the time of the event; it does not refer to an event that hypothetically might have 
caused death if more severe 

Requires inpatient hospitalisation  

Requires prolongation of existing hospitalisation

Results in persistent or significant disability or incapacity 

Is a congenital anomaly/birth defect 

Is deemed serious for any other reason if it is an important medical event when based 
upon appropriate medical judgment which may jeopardise the patient and may 
require medical or surgical intervention to prevent one of the other outcomes listed in 
the above definitions. Examples of such events are intensive treatment in an 
emergency room or at home for allergic bronchospasm, blood dyscrasias or 
convulsions that do not result in hospitalisation or development of dependency or 
abuse
AEs considered ‘Always Serious’
5.2.6.1.3
Cancers of new histology and exacerbations of existing cancer must be classified as a serious 
event regardless of the time since discontinuation of the trial medication and must be reported 


Boehringer Ingelheim
09 Sep 2019
BI Trial No.: 1371-0005
c26448055-04
Trial Protocol
Page 41 of 67
Proprietary confidential information © 2019 Boehringer Ingelheim International GmbH or one or more of its affiliated companies
001-MCS-40-106-RD-13 (6.0) / Saved on: 13 Jun 2018
as described in 5.2.6.2, Subsections ‘AE Collection’ and ‘AE reporting to sponsor and 
timelines’.
In accordance with the European Medicines Agency initiative on Important Medical Events, 
Boehringer Ingelheim has set up a list of further AEs, which, by their nature, can always be 
considered to be ‘serious’ even though they may not have met the criteria of an SAE as 
defined above.
The latest list of ‘Always Serious AEs’ can be found in the eDC system, an electronic data 
capture system which allows the entry of trial data at the trial site. These events should 
always be reported as SAEs as described above.
Adverse events of special interest
5.2.6.1.4
The term adverse events of special interest (AESI) relates to any specific AE that has been 
identified at the project level as being of particular concern for prospective safety monitoring 
and safety assessment within this trial, e.g. the potential for AEs based on knowledge from 
other compounds in the same class. AESIs need to be reported to the sponsor’s 
Pharmacovigilance Department within the same timeframe that applies to SAEs, please see 
Section 5.2.6.2.2.
The following are considered as AESIs:

Hepatic injury
A hepatic injury is defined by the following alterations of hepatic laboratory 
parameters: 
o
An elevation of AST (aspartate transaminase) and/or ALT (alanine 
transaminase) ≥3-fold ULN combined with an elevation of total bilirubin 
≥2-fold ULN measured in the same blood sample, or
o
Aminotransferase (ALT, and/or AST) elevations ≥10 fold ULN
These lab findings constitute a hepatic injury alert and the subjects showing these lab 
abnormalities need to be followed up according to the ‘DILI checklist’ provided in the 
ISF or in eDC, as applicable. In case of clinical symptoms of hepatic injury (icterus, 
unexplained encephalopathy, unexplained coagulopathy, right upper quadrant 
abdominal pain, etc.) without lab results (ALT, AST, total bilirubin) available, the 
Investigator should make sure that these parameters are analysed, if necessary in an 
unscheduled blood test. Should the results meet the criteria of hepatic injury alert, the 
procedures described in the DILI checklist should be followed.


Boehringer Ingelheim
09 Sep 2019
BI Trial No.: 1371-0005
c26448055-04
Trial Protocol
Page 42 of 67
Proprietary confidential information © 2019 Boehringer Ingelheim International GmbH or one or more of its affiliated companies
001-MCS-40-106-RD-13 (6.0) / Saved on: 13 Jun 2018
Intensity (severity) of AEs
5.2.6.1.5
The intensity (severity) of the AE should be judged based on the following:
Mild:
Awareness of sign(s) or symptom(s) that is/are easily tolerated
Moderate:
Sufficient discomfort to cause interference with usual activity
Severe:
Incapacitating or causing inability to work or to perform usual activities
Causal relationship of AEs
5.2.6.1.6
Medical judgment should be used to determine the relationship, considering all relevant 
factors, including pattern of reaction, temporal relationship, de-challenge or re-challenge, 
confounding factors such as concomitant medication, concomitant diseases and relevant 
history.
Arguments that may suggest that there is a reasonable possibility of a causal relationship 
could be:

The event is consistent with the known pharmacology of the drug 

The event is known to be caused by or attributed to the drug class

A plausible time to onset of the event relative to the time of drug exposure

Evidence that the event is reproducible when the drug is re-introduced

No medically sound alternative aetiologies that could explain the event (e.g. pre-
existing or concomitant diseases, or co-medications)

The event is typically drug-related and infrequent in the general population not 
exposed to drugs (e.g. Stevens-Johnson syndrome)

An indication of dose-response (i.e. greater effect size if the dose is increased, smaller 
effect size if dose is reduced)
Arguments that may suggest that there is no reasonable possibility of a causal relationship 
could be:

No plausible time to onset of the event relative to the time of drug exposure is evident 
(e.g. pre-treatment cases, diagnosis of cancer or chronic disease within days / weeks 
of drug administration; an allergic reaction weeks after discontinuation of the drug 
concerned)

Continuation of the event despite the withdrawal of the medication, taking into 
account the pharmacological properties of the compound (e.g. after 5 half-lives). Of 
note, this criterion may not be applicable to events whose time course is prolonged 
despite removing the original trigger

Additional arguments amongst those stated before, like alternative explanation (e.g. 
situations where other drugs or underlying diseases appear to provide a more likely 
explanation for the observed event than the drug concerned)

Disappearance of the event even though the trial drug treatment continues or remains 
unchanged


Boehringer Ingelheim
09 Sep 2019
BI Trial No.: 1371-0005
c26448055-04
Trial Protocol
Page 43 of 67
Proprietary confidential information © 2019 Boehringer Ingelheim International GmbH or one or more of its affiliated companies
001-MCS-40-106-RD-13 (6.0) / Saved on: 13 Jun 2018
5.2.6.2
Adverse event collection and reporting
AE collection
5.2.6.2.1
Upon enrolment into a trial, the subject’s baseline condition is assessed (for instance, by 
documentation of medical history/concomitant diagnoses), and relevant changes from 
baseline are noted subsequently. 
Subjects will be required to report spontaneously any AEs as well as the time of onset, end
time, and intensity of these events. In addition, each subject will be regularly assessed by the 
medical staff throughout the clinical trial and whenever the investigator deems necessary. As 
a minimum, subjects will be questioned for AEs (and concomitant therapies) at the time 
points indicated in the Flow Chart. Assessment will be made using non-specific questions 
such as ‘How do you feel?’. Specific questions will be asked wherever necessary in order to 
more precisely describe an AE.
A carefully written record of all AEs shall be kept by the investigator in charge of the trial. 
Records of AEs shall include data on the time of onset, end time, intensity of the event, and 
any treatment or action required for the event and its outcome.
The following must be collected and documented on the appropriate CRF(s) by the 
investigator:

From signing the informed consent onwards until an individual subject’s end of trial: 
o
All AEs (serious and non-serious) and all AESIs 
o
The only exception to this rule are AEs (serious and non-serious) and AESIs 
in Phase I trials in healthy volunteers, when subjects discontinue from the trial 
due to screening failures prior to administration of any trial medication. In 
these cases, the subjects’ data must be collected at trial site but will not be 
entered in the CRF or trial database and will not be reported in the CTR.

After the individual subject’s end of trial: 
o
The investigator does not need to actively monitor the subject for AEs but 
should only report any occurrence of cancer and related SAEs and related 
AESIs of which the investigator may become aware of by any means of 
communication, e.g. phone call. Those AEs should, however, not be reported 
in the CRF.


Boehringer Ingelheim
09 Sep 2019
BI Trial No.: 1371-0005
c26448055-04
Trial Protocol
Page 44 of 67
Proprietary confidential information © 2019 Boehringer Ingelheim International GmbH or one or more of its affiliated companies
001-MCS-40-106-RD-13 (6.0) / Saved on: 13 Jun 2018
AE reporting to the sponsor and timelines
5.2.6.2.2
The Investigator must report SAEs, AESIs, and non-serious AEs which are relevant for the 
reported SAE or AESI, on the BI SAE form via fax immediately (within 24 hours) to the 
sponsor’s unique entry point (country specific contact details will be provided in the ISF). 
The same timeline applies if follow-up information becomes available. In specific occasions 
the Investigator could inform the sponsor upfront via telephone. This does not replace the
requirement to complete and fax the BI SAE form. 
With receipt of any further information to these events, a follow-up SAE form has to be 
provided. For follow-up information, the same rules and timeline apply as for initial 
information.
Information required
5.2.6.2.3
All (S)AEs, including those persisting after the individual subject’s end of trial, must be 
followed up until they have resolved, have been sufficiently assessed as ‘chronic’ or ‘stable’, 
or no further information can be obtained.
5.3
DRUG CONCENTRATION MEASUREMENTS AND 
PHARMACOKINETICS
5.3.1
Assessment of pharmacokinetics
For the assessment of pharmacokinetics, blood and urine samples will be collected at the time 
points / time intervals indicated in the Flow Chart. The actual sampling times will be 
recorded and used for determination of pharmacokinetic parameters. 
5.3.2
Methods of sample collection
5.3.2.1
Blood sampling for pharmacokinetic analysis
BI 894416
For quantification of BI 894416 concentrations in plasma, 2.7 mL of blood will be drawn
from an antecubital or forearm vein into a K2-EDTA (dipotassium ethylenediaminetetraacetic 
acid)-anticoagulant blood drawing tube at the times indicated in the Flow Chart. Blood will 
be withdrawn by means of either an indwelling venous catheter or by venipuncture with a 
metal needle.
The EDTA-anticoagulated blood samples will be centrifuged for approximately 10 min at 
approximately 2000 g to 4000 g and at 4 to 8 °C. Two plasma aliquots will be obtained and 
stored in polypropylene tubes. The first aliquot should contain at least 0.5 mL of plasma. The 
process from blood collection until transfer of plasma aliquots into the freezer should be 
completed within 90 min, with interim storage of blood samples and aliquots at room 
temperature. The time each aliquot was placed in the freezer will be documented. Until 
transfer on dry ice to the analytical laboratory, the aliquots will be stored upright at 
approximately -20°C or below at the trial site. The second aliquot will be transferred to the 
analytical laboratory after the bioanalyst has acknowledged safe arrival of the first aliquot. At 


Boehringer Ingelheim
09 Sep 2019
BI Trial No.: 1371-0005
c26448055-04
Trial Protocol
Page 45 of 67
Proprietary confidential information © 2019 Boehringer Ingelheim International GmbH or one or more of its affiliated companies
001-MCS-40-106-RD-13 (6.0) / Saved on: 13 Jun 2018
the analytical laboratory, the plasma samples will be stored at approximately -20 °C or below 
until analysis.
At a minimum, the sample tube labels should list BI trial number, subject number, visit, 
planned sampling time, and the analyte “BI 894416”. Further information such as matrix may 
also be provided.
Rifampicin
For quantification of rifampicin concentrations in plasma, 2.7 mL of blood will be drawn 
from an antecubital or forearm vein into a K2-EDTA (dipotassium ethylenediaminetetraacetic 
acid)-anticoagulant blood drawing tube at the times indicated in the Flow Chart. Blood will 
be withdrawn by means of either an indwelling venous catheter or by venepuncture with a 
metal needle.
The EDTA-anticoagulated blood samples will be centrifuged for approximately 10 min at 
approximately 2000 g to 4000 g and at 4 to 8 °C. Two plasma aliquots will be obtained and 
stored in polypropylene tubes. The first aliquot should contain at least 0.5 mL of plasma. The 
process from blood collection until transfer of plasma aliquots into the freezer should be 
completed within 60 min, with interim storage of blood samples and aliquots on ice. The time 
each aliquot was placed in the freezer will be documented. Until transfer on dry ice to the 
analytical laboratory, the aliquots will be stored upright at approximately -70°C or below at 
the trial site. The second aliquot will be transferred to the analytical laboratory after the 
bioanalyst has acknowledged safe arrival of the first aliquot. At the analytical laboratory, the 
plasma samples will be stored at approximately -70°C or below until analysis.
At a minimum, the sample tube labels should list BI trial number, subject number, visit, 
planned sampling time, and the analyte “rifampicin”. Further information such as matrix may 
also be provided.
Further use
After completion of the quantification of BI 894416 or rifampicin in plasma, the plasma 
samples may be used for analysis of rifampicin at additional time points, for analysis of 
metabolites of BI 894416 or rifampicin (including, if applicable, re-analysis of parent 
compound) or for further methodological investigations (e.g. for stability testing). However, 
only data related to the analytes and/or their metabolite(s) including anti-drug antibodies (if 
applicable) will be generated by these additional investigations. The study samples will be 
discarded after completion of the additional investigations but not later than 5 years after the 
CTR is archived.
The results of any further investigations are not planned to be part of the CTR but can be 
included into the CTR if necessary.
 
 


Boehringer Ingelheim
09 Sep 2019
BI Trial No.: 1371-0005
c26448055-04
Trial Protocol
Page 46 of 67
Proprietary confidential information © 2019 Boehringer Ingelheim International GmbH or one or more of its affiliated companies
001-MCS-40-106-RD-13 (6.0) / Saved on: 13 Jun 2018
5.3.3
Analytical determinations
5.3.3.1
Analytical determination of analyte plasma concentration
BI 894416 and rifampicin concentrations in plasma will be determined by a validated LC-
MS/MS (liquid chromatography tandem mass spectrometry) assay. All details of the 
analytical method will be available prior to the start of sample analysis. 


Boehringer Ingelheim
09 Sep 2019
BI Trial No.: 1371-0005
c26448055-04
Trial Protocol
Page 47 of 67
Proprietary confidential information © 2019 Boehringer Ingelheim International GmbH or one or more of its affiliated companies
001-MCS-40-106-RD-13 (6.0) / Saved on: 13 Jun 2018
5.3.3.2
Analytical determination of analyte urine concentration
BI 894416 concentrations in urine will be determined by a validated LC-MS/MS assay. All 
details of the analytical method will be available prior to the start of sample analysis. 
5.4
BIOBANKING
Not applicable.
 
 
 
 
 
 
 
 
5.6
APPROPRIATENESS OF MEASUREMENTS
All measurements performed during this trial are standard measurements and will be 
performed in order to monitor subjects’ safety and to determine pharmacokinetic parameters 
in an appropriate way. The scheduled measurements will allow monitoring of changes in vital 
signs, standard laboratory values, and ECG parameters that might occur as a result of 
administration of trial medication. The safety assessments are standard, are accepted for 
evaluation of safety and tolerability of orally administered drugs, and are widely used in 
clinical trials. The pharmacokinetic parameters and measurements outlined in Section 5.3. 
2.1.2, 2.1.3, and 2.2.2.1 are generally used assessments of drug exposure. 
Due to reversible neurologic effects observed in dog studies at high exposures, a neurological 
examination is performed at Screening to ensure that no subject with a clinically relevant 
finding in the neurological examination is included into the trial. Upon investigator judgment, 
additional neurological examinations may be added at any time during the trial, for individual 
subjects or for the whole treatment group.


Boehringer Ingelheim
09 Sep 2019
BI Trial No.: 1371-0005
c26448055-04
Trial Protocol
Page 48 of 67
Proprietary confidential information © 2019 Boehringer Ingelheim International GmbH or one or more of its affiliated companies
001-MCS-40-106-RD-13 (6.0) / Saved on: 13 Jun 2018
6.
INVESTIGATIONAL PLAN
6.1
VISIT SCHEDULE
Exact times of measurements outside the permitted time windows will be documented. The 
acceptable time windows for screening and the end of trial examination are provided in the 
Flow Chart.
Study measurements and assessments scheduled to occur ‘before’ trial medication 
administration on Day 1 are to be performed and completed within a 3 h-period prior to the 
trial drug administration.
The acceptable deviation from the scheduled time for vital signs, ECG, and laboratory tests 
will be ± 60 min.
If scheduled in the Flow Chart at the same time as a meal, blood sampling, vital signs, and 
12-lead ECG recordings have to be done first. Furthermore, if several measurements 
including venepuncture are scheduled for the same time, venepuncture should be the last of 
the measurements due to its inconvenience to the subject and possible influence on 
physiological parameters.
For planned blood sampling times, refer to the Flow Chart. While these nominal times should 
be adhered to as closely as possible, the actual sampling times will be recorded and used for 
the determination of pharmacokinetic parameters.
For time point 34 h (planned time) after BI 894416 administration, a time window of 
± 60 min will be allowed for PK blood sampling. For time point 48 h (planned time) after 
BI 894416 administration, a time window of ± 120 min will be allowed for PK blood 
sampling.
If a subject misses an appointment, it will be rescheduled if possible. The relevance of 
measurements outside the permitted time windows will be assessed no later than at the Report 
Planning Meeting.
6.2
DETAILS OF TRIAL PROCEDURES AT SELECTED VISITS
6.2.1
Screening period
After having been informed about the trial, all subjects will provide written informed consent 
in accordance with GCP and local legislation prior to enrolment in the study.
For information regarding laboratory tests (including drug and virus screening), ECG, vital 
signs, physical examination, and neurological examination, refer to Sections 5.2.1 to 5.2.5.
6.2.2
Treatment periods
Samples for genotyping will be taken from all volunteers prior to first drug administration in 
period 1 (for details, see Section 5.5.1).
Each subject is expected to participate in 2 treatment periods (Period 1: Days 1 to 3; Period 2: 
Days -7 to 3). At least 10 days will separate administrations of BI 894416 in the first and 
second treatment periods.


Boehringer Ingelheim
09 Sep 2019
BI Trial No.: 1371-0005
c26448055-04
Trial Protocol
Page 49 of 67
Proprietary confidential information © 2019 Boehringer Ingelheim International GmbH or one or more of its affiliated companies
001-MCS-40-106-RD-13 (6.0) / Saved on: 13 Jun 2018
On Day 1 of treatment period 1 / Day -1 of treatment period 2, study participants will be 
admitted to the trial site and kept under close medical surveillance for at least 24 h following 
BI 894416 administration. The subjects will then be allowed to leave the trial site after formal 
assessment and confirmation of their fitness. 
In addition, on Day -7 of treatment period 2, subjects will be admitted to the trial site and 
kept under close medical surveillance for at least 2 h following the first rifampicin 
administration. The subjects will then be allowed to leave the trial site after formal 
assessment and confirmation of their fitness. 
On all other study days, subjects will be treated in an ambulatory fashion.
For details on time points and procedures for collection of plasma and urine samples for PK 
analysis, refer to Flow Chart and Section 5.3.2.
The safety measurements performed during the treatment period are specified in Section 5.2
of this protocol and in the Flow Chart. For details on times of all other trial procedures, refer 
to the Flow Chart. AEs and concomitant therapy will be assessed continuously from 
screening until the end of trial examination.
6.2.3
Follow-up period and trial completion
For AE assessment, laboratory tests, recording of ECG and vital signs, physical examination, 
and neurological examination during the follow-up period, see Sections 5.2.1 to 5.2.6.
Subjects who discontinue treatment before the end of the planned treatment period should 
undergo the EoTrial Visit.
All abnormal values (including laboratory parameters) that are assessed as clinically relevant 
by the investigator will be monitored using the appropriate tests until a return to a medically 
acceptable level is achieved. (S)AEs persisting after a subject’s EoTrial Visit must be 
followed until they have resolved, have been sufficiently characterised, or no further 
information can be obtained.


Boehringer Ingelheim
09 Sep 2019
BI Trial No.: 1371-0005
c26448055-04
Trial Protocol
Page 50 of 67
Proprietary confidential information © 2019 Boehringer Ingelheim International GmbH or one or more of its affiliated companies
001-MCS-40-106-RD-13 (6.0) / Saved on: 13 Jun 2018
7.
STATISTICAL METHODS AND DETERMINATION OF
SAMPLE SIZE
7.1
STATISTICAL DESIGN – MODEL
The main objective of this trial is to investigate the effect of rifampicin on the 
pharmacokinetics of BI 894416 (50 mg) in plasma when given as oral single dose together 
with multiple oral doses of rifampicin (600 mg) (Test, T) as compared to when given alone as 
oral single dose (Reference, R) on the basis of the primary and secondary pharmacokinetic 
endpoints, as listed in Section 2.1.2 and 2.1.3. The trial is designed to allow intra-subject 
comparisons and will be evaluated statistically by use of a linear model for logarithmically 
transformed PK endpoints.
 
The assessment of safety and tolerability is a further objective of this trial, and will be 
evaluated by descriptive statistics for the parameters specified in Section 2.2.2.2.
7.2
NULL AND ALTERNATIVE HYPOTHESES
The effect of rifampicin on the pharmacokinetics of BI 894416 in plasma after test vs. 
reference treatment will be estimated by the ratios of the geometric means (test/reference),
and their corresponding 2-sided 90% confidence intervals (CIs) will be provided. This 
method corresponds to the two one-sided t-test procedure, each at the 5% significance level. 
Since the main focus is on estimation and not testing, a formal hypothesis test and associated 
acceptance range is not specified.
7.3
PLANNED ANALYSES
Analysis sets
Statistical analyses will be based on the following analysis sets:

Treated set (TS): The treated set includes all subjects who were treated with at least 
one dose of study drug. The treated set will be used for safety analyses.
Pharmacokinetic parameter analysis set (PKS): This set includes all subjects in the 
treated set (TS) who provide at least one PK endpoint that was defined as primary or 
secondary and was not excluded due to a protocol deviation relevant to the evaluation 
of PK or due to PK non-evaluability (as specified in the following subsection 
‘Pharmacokinetics’). Thus, a subject will be included in the PKS, even if he 
contributes only one PK parameter value for one period to the statistical assessment.
Descriptive and model based analyses of PK parameters will be based on the PKS.
Adherence to the protocol will be assessed by the trial team. Important protocol deviation
(IPD) categories will be suggested in the IQRMP, IPDs will be identified no later than in the 
Report Planning Meeting, and the IPD categories will be updated as needed.


Boehringer Ingelheim
09 Sep 2019
BI Trial No.: 1371-0005
c26448055-04
Trial Protocol
Page 51 of 67
Proprietary confidential information © 2019 Boehringer Ingelheim International GmbH or one or more of its affiliated companies
001-MCS-40-106-RD-13 (6.0) / Saved on: 13 Jun 2018
Pharmacokinetics
The pharmacokinetic parameters listed in Section 2.1 for drug BI 894416 will be calculated 
according to the relevant SOP of the Sponsor (001-MCS-36-472). 
Plasma concentration data and parameters of a subject will be included in the statistical 
pharmacokinetic (PK) analyses if they are not flagged for exclusion due to a protocol 
deviation relevant to the evaluation of PK (to be decided no later than in the Report Planning 
Meeting) or due to PK non-evaluability (as revealed during data analysis, based on the 
criteria specified below). Exclusion of a subject’s data will be documented in the CTR.
Relevant protocol deviations may be

Incorrect trial medication taken, i.e. the subject received at least one dose of trial
medication the subject was not assigned to

Incorrect dose of trial medication taken

Use of restricted medications
Plasma concentrations and/or parameters of a subject will be considered as non-evaluable, if 
for example

The subject experienced emesis that occurred at or before two times median tmax of 
the respective treatment (Median tmax is to be determined excluding the subjects 
experiencing emesis),

A predose concentration of BI 894416 is >5% Cmax value of that subject in the 
respective treatment period

Missing samples/concentration data at important phases of PK disposition curve
Plasma concentration data and parameters of a subject which is flagged for exclusion will be 
reported with its individual values but will not be included in the statistical analyses. 
Descriptive and inferential statistics of PK parameters will be based on the PKS.
Only concentration values within the validated concentration range and actual sampling times 
will be used for the calculation of pharmacokinetic parameters. Concentrations used in the 
pharmacokinetic calculations will be in the same format provided in the bioanalytical report, 
(that is, to the same number of decimal places provided in the bioanalytical report). 
7.3.1
Primary endpoint analyses
Primary analyses
The primary endpoints (refer to Section 2.1.2) will be calculated according to BI Standard 
Operating Procedure (SOP) ‘Standards and processes for analyses performed within Clinical 
Pharmacokinetics/ Pharmacodynamics’ (001-MCS-36-472).
The statistical model used for the analysis of the primary endpoints will be a mixed effects
model on the logarithmic scale. That is, the PK endpoints will be log-transformed (natural 
logarithm) prior to fitting the mixed effects model. This model will include effects accounting 
for the following sources of variation: subject and treatment. The effect 'subjects' will be 


Boehringer Ingelheim
09 Sep 2019
BI Trial No.: 1371-0005
c26448055-04
Trial Protocol
Page 52 of 67
Proprietary confidential information © 2019 Boehringer Ingelheim International GmbH or one or more of its affiliated companies
001-MCS-40-106-RD-13 (6.0) / Saved on: 13 Jun 2018
considered as random, whereas treatment will be considered as fixed. The model is described 
by the following equation:
ykm = +  sm + k + ekm, where
ykm = logarithm of response measured on subject m receiving treatment k,
= the overall mean,
sm = the effect associated with the mth subject, m = 1, 2, ..., n
k = the kth treatment effect, k = 1, 2,
ekm = the random error associated with the mth subject who received
treatment k.
where s ~ N(0, σ
) i.i.d., e ~ N(0, σ
 ) i.i.d. and sm, ekm are independent random 
variables.
Point estimates for the ratios of the geometric means (test/reference) for the primary 
endpoints (see Section 2.1) and their two-sided 90% confidence intervals (CIs) will be 
provided.
For each endpoint, the difference between the expected means for log(T)-log(R) will be 
estimated by the difference in the corresponding adjusted means (Least Squares Means).
Additionally their two-sided 90% confidence intervals will be calculated based on the 
residual error from the mixed effects model and quantiles from the t-distribution. These 
quantities will then be back-transformed to the original scale to provide the point estimate 
and 90% CIs for each endpoint.
 
In addition to the model based approach all parameters will be calculated and analysed 
descriptively.
7.3.2
Secondary endpoint analyses
The secondary endpoints (refer to Section 2.1.3) will be calculated according to the BI SOP 
‘Standards and processes for analyses performed within Clinical Pharmacokinetics/ 
Pharmacodynamics’ (001-MCS-36-472) and will be assessed statistically using the same 
methods as described for the primary endpoints.


Boehringer Ingelheim
09 Sep 2019
BI Trial No.: 1371-0005
c26448055-04
Trial Protocol
Page 53 of 67
Proprietary confidential information © 2019 Boehringer Ingelheim International GmbH or one or more of its affiliated companies
001-MCS-40-106-RD-13 (6.0) / Saved on: 13 Jun 2018
7.3.4
Safety analyses
Safety will be analysed based on the assessments described in Section 2.2.2.2. All treated 
subjects (TS, refer to Section 7.2) will be included in the safety analysis. Safety analyses will 
be descriptive in nature and based on BI standards. No hypothesis testing is planned.
For all analyses, the treatment actually administered (= treatment at onset) to the subject will 
be used (any deviations from the randomised treatment will be discussed in the minutes of the 
Report Planning Meeting).
Treatments will be compared in a descriptive way. Tabulations of frequencies/proportions 
will be used to evaluate categorical (qualitative) data, and tabulations of descriptive statistics 
will be used to analyse continuous (quantitative) data.
Measurements (such as ECG, vital signs, or laboratory parameters) or AEs will be assigned to 
treatments (see Section 4.1) based on the actual treatment at the planned time of the 
measurement or on the recorded time of AE onset (concept of treatment emergent AEs).
Therefore, measurements planned or AEs recorded prior to first intake of trial medication in 
period 1 will be assigned to the screening period, those between treatment with BI 894416 in 
period 1 and first treatment with rifampicin in period 2 are attributed to the treatment interval 
“BI 894416 alone”, those between first treatment with rifampicin in period 2 and treatment 
with BI 894416 in period 2 are attributed to the treatment interval “rifampicin alone” and 
those occurring between treatment with BI 894416 in period 2 and the individual subject’s 
end of trial are attributed to the treatment interval “BI 894416 + rifampicin“. These 
assignments including the corresponding time intervals will be defined in detail in the TSAP. 
Note that AEs occurring after the last per protocol contact but entered before final database 
lock will be reported to Pharmacovigilance only and will not be captured in the trial database.
Additionally, further treatment intervals (analysing treatments) may be defined in the TSAP 
in order to provide summary statistics for time intervals, such as combined treatments, on-
treatment totals, or periods without treatment effects (such as screening and follow-up 
intervals).
Adverse events will be coded using the Medical Dictionary for Regulatory Activities 
(MedDRA). Frequency, severity, and causal relationship of AEs will be tabulated by 
treatment, system organ class, and preferred term. SAEs, AESIs (see Section 5.2.6.1), and 
other significant AEs (according to ICH E3) will be listed separately.
Previous and concomitant therapies will be presented per treatment group without 
consideration of time intervals and treatment periods.
Laboratory data will be compared to their reference ranges. Values outside the reference 
range as well as values defined as possibly clinically significant will be highlighted in the 
listings. Additionally, differences from baseline will be evaluated.
Vital signs or other safety-relevant data will be assessed with regard to possible on-treatment 
changes from baseline.
Relevant ECG findings will be reported as AEs.


Boehringer Ingelheim
09 Sep 2019
BI Trial No.: 1371-0005
c26448055-04
Trial Protocol
Page 54 of 67
Proprietary confidential information © 2019 Boehringer Ingelheim International GmbH or one or more of its affiliated companies
001-MCS-40-106-RD-13 (6.0) / Saved on: 13 Jun 2018
7.4
INTERIM ANALYSES
No interim analysis is planned.
7.5
HANDLING OF MISSING DATA
7.5.1
Safety
It is not planned to impute missing values for safety parameters.
7.5.2
Pharmacokinetics
Handling of missing PK data will be performed according to the relevant Corporate 
Procedure (001-MCS-36-472).
PK parameters that cannot be reasonably calculated based on the available drug 
concentration-time data will not be imputed.
7.6
RANDOMISATION
In this trial subjects receive both treatments in the same order, thus no randomization for the
treatment assignment is performed (see also Section 4.1.3).
7.7
DETERMINATION OF SAMPLE SIZE
It is planned to enter a total of 16 subjects in the trial, including up to 4 non PK evaluable 
subjects. The planned sample size is not based on a power calculation but is considered 
sufficient to achieve the aims of this exploratory trial. With this sample size, the following 
precision in estimating the ratio of geometric means (test/reference) can be expected with 
95% probability. Precision is defined as the ratio of upper CI limit to the relative BA 
estimate. Note that the precision is independent of the actual ratio of geometric means.
The intra-individual coefficient of variation (gCV) was estimated from inter-individual gCV 
from preliminary PK data of the SRD part of a previous trial using the 54 mg dose (data on 
file). The observed inter-individual gCV was roughly 27% for AUC0-∞and 29% for AUC0-tz. 
Assuming a within-subject correlation 0.8 for AUC0-∞and AUC0-tz, the estimated upper 70% 
CI of the intra-individual gCV was roughly 17% for AUC0-∞and 15% for AUC0-tz.
Assuming a gCV of 17% for BI 894416 and given a sample size of 12 subjects with 
evaluable data for primary analysis, the precision of the two-sided 90% confidence interval of 
the bioavailability ratio will be approximately 1.18 for a greater gCV of 22%, the precision 
would still be approximately 1.24. Table 7.7: 1 provides an overview of the achievable 
precision for estimating the ratio of geometric means (test/reference). For illustrative 
purposes, the expected 90% confidence intervals with 95% tolerance probability are 
displayed for different values of the ratios T/R of geometric means.


Boehringer Ingelheim
09 Sep 2019
BI Trial No.: 1371-0005
c26448055-04
Trial Protocol
Page 55 of 67
Proprietary confidential information © 2019 Boehringer Ingelheim International GmbH or one or more of its affiliated companies
001-MCS-40-106-RD-13 (6.0) / Saved on: 13 Jun 2018
Table 7.7: 1
Precision that can be expected with 95% probability and illustrative 
two-sided 90% confidence intervals around the ratios of geometric 
means (T/R) for different gCVs in a one-way crossover trial (N=12)
gCV [%]
Precision upper 
CL / relative BA 
estimate
Ratio [%]*
Lower CL [%]
Upper CL [%]
12
1.12
100
88.94
112.44
12
1.12
150
133.41
168.66
12
1.12
200
177.87
224.88
12
1.12
400
355.75
449.76
17
1.18
100
84.75
118.00
17
1.18
150
127.12
177.00
17
1.18
200
169.49
236.00
17
1.18
400
338.99
472.00
22
1.24
100
80.80
123.76
22
1.24
150
121.20
185.64
22
1.24
200
161.60
247.52
22
1.24
400
323.21
495.04
*Ratio of geometric means (test/reference) for a PK endpoint is defined by exp(T)/exp(R).
The expected 90% confidence interval limits in the table were derived by
CI limit, = exp(ln(θ) ± ω),
with θ being the ratio (T/R) on original scale and ω the distance from the estimate θ to either 
confidence interval limit on the log-scale, which was obtained from the achievable precision 
on the original scale.
The calculation was performed as described by Julious [R11-5230] using R Version 3.5.1.


Boehringer Ingelheim
09 Sep 2019
BI Trial No.: 1371-0005
c26448055-04
Trial Protocol
Page 56 of 67
Proprietary confidential information © 2019 Boehringer Ingelheim International GmbH or one or more of its affiliated companies
001-MCS-40-106-RD-13 (6.0) / Saved on: 13 Jun 2018
8.
INFORMED CONSENT, TRIAL RECORDS, DATA 
PROTECTION, PUBLICATION POLICY, AND 
ADMINISTRATIVE STRUCTURE
The trial will be carried out in compliance with the protocol, the ethical principles laid down 
in the Declaration of Helsinki, in accordance with the ICH Harmonized Guideline for Good 
Clinical Practice (GCP), relevant BI Standard Operating Procedures (SOPs), the EU 
regulation 536/2014, and other relevant regulations. Investigators and site staff must adhere 
to these principles.
Standard medical care (prophylactic, diagnostic, and therapeutic procedures) remains the 
responsibility of the subject’s treating physician.
The investigator will inform the sponsor immediately of any urgent safety measures taken to 
protect the trial subjects against any immediate hazard, as well as of any serious breaches of 
the protocol or of ICH GCP.
The Boehringer Ingelheim transparency and publication policy can be found on the following 
web page: trials.boehringer-ingelheim.com. As a general rule, no trial results should be 
published prior to archiving of the CTR.
The terms and conditions of the insurance coverage are made available to the investigator and 
the subjects, and are stored in the ISF.
8.1
TRIAL APPROVAL, SUBJECT INFORMATION, INFORMED CONSENT
This trial will be initiated only after all required legal documentation has been reviewed and 
approved by the respective Institutional Review Board (IRB / Independent Ethics Committee 
(IEC and competent authority (CA) according to national and international regulations. The 
same applies for the implementation of changes introduced by amendments.
Prior to a subject’s participation in the trial, written informed consent must be obtained from 
each subject (or the subject’s legally accepted representative) according to ICH-GCP and to 
the regulatory and legal requirements of the participating country. Each signature must be 
personally dated by each signatory and the informed consent and any additional subject-
information form retained by the investigator as part of the trial records. A signed copy of the 
informed consent and any additional subject information must be given to each subject or the 
subject’s legally accepted representative.
The subject must be given sufficient time to consider participation in the trial. The 
investigator or delegate obtains written consent of the subject’s own free will with the 
informed consent form after confirming that the subject understands the contents. The 
investigator or 
 delegate must sign (or place a seal on) and date the informed consent form. 
If a trial collaborator has given a supplementary explanation, the trial collaborator also signs 
(or places a seal on) and dates the informed consent.
Re-consenting may become necessary when new relevant information becomes available and 
should be conducted according to the sponsor’s instructions.
The consent and re-consenting process should be properly documented in the source 
documentation.


Boehringer Ingelheim
09 Sep 2019
BI Trial No.: 1371-0005
c26448055-04
Trial Protocol
Page 57 of 67
Proprietary confidential information © 2019 Boehringer Ingelheim International GmbH or one or more of its affiliated companies
001-MCS-40-106-RD-13 (6.0) / Saved on: 13 Jun 2018
8.2
DATA QUALITY ASSURANCE
A risk-based approach is used for trial quality management. It is initiated by the assessment 
of critical data and processes for trial subject protection and reliability of the results as well as 
identification and assessment of associated risks. An Integrated Quality and Risk 
Management Plan documents the rationale and strategies for risk management during trial 
conduct including monitoring approaches, vendor management and other processes focusing 
on areas of greatest risk. 
Continuous risk review and assessment may lead to adjustments in trial conduct, trial design 
or monitoring approaches. 
A quality assurance audit/inspection of this trial may be conducted by the sponsor, sponsor’s 
designees, or by IRB / IEC or by regulatory authorities. The quality assurance auditor will 
have access to all medical records, the investigator’s trial-related files and correspondence, 
and the informed consent documentation of this clinical trial.
8.3
RECORDS
CRFs for individual subjects will be provided by the sponsor. For drug accountability, refer 
to Section 4.1.8.
8.3.1
Source documents
In accordance with regulatory requirements, the investigator should prepare and maintain 
adequate and accurate source documents and trial records for each trial subject that include 
all observations and other data pertinent to the investigation. Source data as well as reported 
data should follow the ‘ALCOA principles’ and be attributable, legible, contemporaneous, 
original, and accurate. Changes to the data should be traceable (audit trail).
Data reported on the CRF must be consistent with the source data or the discrepancies must 
be explained.
Before providing any copy of subjects’ source documents to the sponsor, the investigator 
must ensure that all subject identifiers (e.g., subject’s name, initials, address, phone number, 
and social security number) have properly been removed or redacted to ensure subject 
confidentiality.
If the subject is not compliant with the protocol, any corrective action (e.g. re-training) must 
be documented in the subject file.
For the CRF, data must be derived from source documents, for example:

Subject identification: sex, year of birth (in accordance with local laws and 
regulations)

Subject participation in the trial (substance, trial number, subject number, date subject 
was informed)

Dates of subject’s visits, including dispensing of trial medication

Medical history (including trial indication and concomitant diseases, if applicable)

Medication history


Boehringer Ingelheim
09 Sep 2019
BI Trial No.: 1371-0005
c26448055-04
Trial Protocol
Page 58 of 67
Proprietary confidential information © 2019 Boehringer Ingelheim International GmbH or one or more of its affiliated companies
001-MCS-40-106-RD-13 (6.0) / Saved on: 13 Jun 2018

AEs and outcome events (onset date [mandatory], and end date [if available])

SAEs (onset date [mandatory], and end date [if available])

Concomitant therapy (start date, changes)

Originals or copies of laboratory results and other imaging or testing results, with 
proper documented medical evaluation (in validated electronic format, if available)

ECG results (original or copies of printouts)

Completion of subject’s participation in the trial (end date; in case of premature 
discontinuation, document the reason for it, if known)

Prior to allocation of a subject to a treatment into a clinical trial, there must be 
documented evidence in the source data (e.g. medical records) that the trial participant 
meets all inclusion criteria and does not meet any exclusion criteria. The absence of 
records (either medical records, verbal documented feedback of the subject or testing 
conducted specific for a protocol) to support inclusion/exclusion criteria does not 
make the subject eligible for the clinical trial.
8.3.2
Direct access to source data and documents
The investigator /institution will allow site trial-related monitoring, audits, IRB / IEC review 
and regulatory inspections. Direct access must be provided to the CRF and all source 
documents/data, including progress notes, copies of laboratory and medical test results, which 
must be available at all times for review by the Clinical Research Associate, auditor and 
regulatory inspector (e.g. FDA). They may review all CRFs and informed consents. The 
accuracy of the data will be verified by direct comparison with the source documents 
described in Section 8.3.1. The sponsor will also monitor compliance with the protocol and 
GCP.
8.3.3
Storage period of records
Trial site:
The trial site(s) must retain the source and essential documents (including ISF) according to 
the local requirements valid at the time of the end of the trial.
Sponsor:
The sponsor must retain the essential documents according to the sponsor’s SOPs.
8.4
EXPEDITED REPORTING OF ADVERSE EVENTS
BI is responsible to fulfil their legal and regulatory reporting obligation in accordance with 
regulatory requirements.
8.5
STATEMENT OF CONFIDENTIALITY AND SUBJECT PRIVACY
Individual subject data obtained as a result of this trial is considered confidential and 
disclosure to third parties is prohibited with the exceptions noted in Section 8.7. 


Boehringer Ingelheim
09 Sep 2019
BI Trial No.: 1371-0005
c26448055-04
Trial Protocol
Page 59 of 67
Proprietary confidential information © 2019 Boehringer Ingelheim International GmbH or one or more of its affiliated companies
001-MCS-40-106-RD-13 (6.0) / Saved on: 13 Jun 2018
Data protection and data security measures are implemented for the collection, storage and 
processing of patient data in accordance with the principles 6 and 12 of the WHO GCP 
handbook.
Personalised treatment data may be given to the subject’s personal physician or to other 
appropriate medical personnel responsible for the subject’s welfare. Data generated at the site 
as a result of the trial need to be available for inspection on request by the participating 
physicians, the sponsor’s representatives, by the IRB / IEC and the regulatory authorities.
8.5.1
Collection, storage and future use of biological samples and corresponding 
data
Measures are in place to comply with the applicable rules for the collection, storage and 
future use of biological samples and clinical data, in particular

Sample and data usage has to be in accordance with the informed consent

The BI-internal facilities storing biological samples from clinical trial participants as 
well as the external banking facility are qualified for the storage of biological samples 
collected in clinical trials.

An appropriate sample and data management system, incl. audit trail for clinical data 
and samples to identify and destroy such samples according to ICF is in place

A fit for the purpose documentation (e.g., biomarker proposal, analysis plan and 
report) ensures compliant usage

If applicable, a fit for purpose approach will be used for assay/equipment validation 
depending on the intended use of the biomarker data
Samples and/or data may be transferred to third parties and other countries as specified in the 
ICF
8.6
TRIAL MILESTONES
The start of the trial is defined as the date of the enrolment of the first subject in the trial.
The end of the trial is defined as the ‘date of the last visit of the last subject in whole trial’ 
(‘Last Subject Completed’) or ‘end date of the last open AE’ or ‘date of the last follow-up 
test’ or ‘date of an AE has been decided as sufficiently followed-up’, whichever is latest.
Early termination of the trial is defined as the premature termination of the trial for any 
reason before the end of the trial as specified in this protocol.
Temporary halt of the trial is defined as any unplanned interruption of the trial by the 
sponsor with the intention to resume it.
Suspension of the trial is defined as an interruption of the trial based on a Health Authority 
request.
The EC/competent authority in each participating EU member state will be notified about the 
trial milestones according to the laws of each member state. 
A final report of the clinical trial data will be written only after all subjects have completed 
the trial in all countries (EU or non-EU), so that all data can be incorporated and considered 
in the report.


Boehringer Ingelheim
09 Sep 2019
BI Trial No.: 1371-0005
c26448055-04
Trial Protocol
Page 60 of 67
Proprietary confidential information © 2019 Boehringer Ingelheim International GmbH or one or more of its affiliated companies
001-MCS-40-106-RD-13 (6.0) / Saved on: 13 Jun 2018
The sponsor will submit to the EU database a summary of the final trial results within one 
year from the end of a clinical trial as a whole, regardless of the country of the last patient 
(EU or non-EU).
8.7
ADMINISTRATIVE STRUCTURE OF THE TRIAL
The trial is sponsored by Boehringer Ingelheim (BI).
The trial will be conducted at
,
, under the supervision of the 
Principal Investigator. Relevant documentation on the participating (Principal) Investigators 
(e.g. their curricula vitae) will be filed in the ISF.
BI has appointed a Clinical Trial Leader, responsible for coordinating all required trial 
activities, in order to 

Manage the trial in accordance with applicable regulations and internal SOPs

Direct the clinical trial team in the preparation, conduct, and reporting of the trial

ensure appropriate training and information of clinical trial managers (CTM), Clinical 
Research Associates, and investigators of participating trial sites
The trial medication will be provided by the Clinical Trial Supplies Unit, BI Pharma GmbH 
& Co. KG, Biberach, Germany (BI 894416) or will be obtained by the clinical trial site from 
a public pharmacy (rifampicin).
Safety laboratory tests will be performed by the local laboratory of the trial site 
 
).
Analysis of BI 894416 concentrations in plasma and urine will be performed at 
, 
Analysis of rifampicin concentrations in plasma will be performed at 
 
On-site monitoring will be performed by BI or a contract research organisation appointed by 
BI.
Data management and statistical evaluation will be done by BI or a contract research 
organization appointed by BI according to BI SOPs.
Tasks and functions assigned in order to organise, manage, and evaluate the trial are defined 
according to BI SOPs. A list of responsible persons and relevant local information can be
found in the ISF.


Boehringer Ingelheim
09 Sep 2019
BI Trial No.: 1371-0005
c26448055-04
Trial Protocol
Page 61 of 67
Proprietary confidential information © 2019 Boehringer Ingelheim International GmbH or one or more of its affiliated companies
001-MCS-40-106-RD-13 (6.0) / Saved on: 13 Jun 2018
9.
REFERENCES 
9.1
PUBLISHED REFERENCES
P03-08008
Niemi M, Backman JT, Fromm MF, Neuvonen PJ, Kivisto KT. 
Pharmacokinetic interactions with rifampicin: clinical relevance. Clin 
Pharmacokinet 2003;42(9):819-850.
P08-01263
Expert panel report 3: guidelines for the diagnosis and management of 
asthma: full report 2007 (NIH publication no. 07-4051, revised August 
2007). http://www.nhlbi.nih.gov ; Bethesda: U.S. Department of Health and 
Human Services, National Institutes of Health, National Heart, Lung and 
Blood Institute; 2007.
P14-07656
Mueller F, Fromm MF. Transporter-mediated drug-drug interactions. 
Pharmacogenomics 2011;12(7):1017-1037.
R11-5230
Julious SA. Sample sizes for clinical trials. Boca Raton: Taylor & Francis 
Group; 2010.
R14-4230
Wenzel SE. Asthma phenotypes: the evolution from clinical to molecular 
approaches. Nature Med 2012;18(5):716-725.
R15-4770
Blancato J, Graves A, Rashidi B, Moroni M, Tchobe L, Ozdemirli M, 
Kallakury B, Makambi KH, Marian C, Mueller SC. SYK allelic loss and 
the role of Syk-regulated genes in breast cancer survival. Plos One 
2014;9(2):e87610
R15-5470
Mocsai A, Ruland J, Tybulewicz VLJ. The SYK tyrosine kinase: a crucial 
player in diverse biological functions. Nat Rev Immunol 2010;10(6):387-
402.
R15-5888
Pelaia G, Vatrella A, Busceti MT, Gallelli L, Calabrese C, Terracciano R, 
Maselli R. Cellular mechanisms underlying eosinophilic and neutrophilic 
airway inflammation in asthma. Mediators Inflamm 2015;2015:879783
R16-0945
Fahy JV. Type 2 inflammation in asthma - present in most, absent in many. 
Nat Rev Immunol 2015;15:57-65.
R16-4459
Krisenko MO, Geahlen RL. Calling in SYK: SYK's dual role as a tumor 
promoter and tumor suppressor in cancer. Biochim Biophys Acta Mol Cell 
Res 2015;1853(1):254-263.
R16-5240
Boylan B, Gao C, Rathore V, Gill JC, Newman DK, Newman PJ. 
Identification of FcgammaRIIa as the ITAM-bearing receptor mediating 
alphaIIbbeta3 outside-in integrin signaling in human platelets. Blood 
2008;112(7):2780-2786.
R16-5298
Alsadeq A, Hobeika E, Medgyesi D, Klaesener K, Reth M. The role of the 
Syk/Shp-1 kinase-phosphatase equilibrium in B cell development and 
signaling. J Immunol 2014;193:268-276.


Boehringer Ingelheim
09 Sep 2019
BI Trial No.: 1371-0005
c26448055-04
Trial Protocol
Page 62 of 67
Proprietary confidential information © 2019 Boehringer Ingelheim International GmbH or one or more of its affiliated companies
001-MCS-40-106-RD-13 (6.0) / Saved on: 13 Jun 2018
R18-0241
Guidance for industry: clinical drug interaction studies - study design, data 
analysis, and clinical implications (draft guidance, this guidance document 
is being distributed for comment purposes only) (October 2017, clinical 
pharmacology). 
https://www.fda.gov/downloads/drugs/guidances/ucm292362.pdf (access 
date: 19 January 2018) ; Silver Spring: U.S. Department of Health and 
Human Services, Food and Drug Administration, Center for Drug 
Evaluation and Research (CDER); 2017.
R19-2541
Eremfat 600 mg (Riemser), verschreibungspflichtig (Fachinformation 
(Zusammenfassung der Merkmale des Arzneimittels/SPC), Stand der 
Information: 03.2019).
R94-1529 
Chow SC, Liu JP. Design and Analysis of Bioavailability and 
Bioequivalence Studies. New York: Marcel Dekker Inc; 1992.
9.2
UNPUBLISHED REFERENCES
001-MCS-36-472 Standards and processes for analyses performed within Clinical 
Pharmacokinetics/Pharmacodynamics. Current version
c03536505-04
 
 Investigator Brochure: BI 894416 
Asthma. 04 March 2019.
n00240179
 BI 894416: 
Exploratory 15 day oral (gavage) toxicity study in male rats. Nonclinical 
Report. 13B105. 29 June 2015.
n00243171
 Assessment of pro-proliferative effects of the 
SYK inhibitor BI 1002494 on human breast cancer cell lines and in silico 
genetic evaluation of SYK for tumour suppressor characteristics using data 
from breast cancer patient databases. Nonclinical Report. 2016-i-r-resp3-
report1. 11 July 2016.
n00245394 
 BI 894416: Dose Escalation in Dogs with Assessment of 
Electroencephalography and Nerve Conduction Velocity. Nonclinical 
Report. 15R160. 21 February 2017.
U09-1349-01
 
Relative bioavailability of single doses of 150 mg dabigatran etexilate 
(capsule) when administered alone, after seven days of dosing with 600 mg 
rifampicin (tablet), and seven days and fourteen days after last 
administration of rifampicin in healthy male and female volunteers (an open 
label, fixed sequence, Phase I study). Clinical Trial Report. 1160.100. 29 
October 2009.
U10-1328-01
 An open-label, 
2-period, fixed-sequence, phase I trial to evaluate the effect of multiple 
doses of rifampicin on the multiple-dose pharmacokinetics of linagliptin. 
Clinical Trial Report. 1218.67. 17 February 2010.


Boehringer Ingelheim
09 Sep 2019
BI Trial No.: 1371-0005
c26448055-04
Trial Protocol
Page 63 of 67
Proprietary confidential information © 2019 Boehringer Ingelheim International GmbH or one or more of its affiliated companies
001-MCS-40-106-RD-13 (6.0) / Saved on: 13 Jun 2018
U12-1140-01
 Relative bioavailability of a 
single oral dose of 40 mg afatinib given alone and after multiple doses of 
rifampicin – an openlabel, two-period, fixed sequence clinical phase I trial 
in healthy male volunteers. Clinical Trial Report. 1200.152. 07 February 
2012.
U13-1478-01
 Relative 
bioavailability of a single oral dose of nintedanib given alone and in 
combination with multiple oral doses of rifampicin in healthy male 
volunteers (an open-label, two-period, fixed-sequence Phase I trial). Clincal 
Trial Report. 1199.162. 08 August 2013.


Boehringer Ingelheim
09 Sep 2019
BI Trial No.: 1371-0005
c26448055-04
Trial Protocol
Page 64 of 67
Proprietary confidential information © 2019 Boehringer Ingelheim International GmbH or one or more of its affiliated companies
001-MCS-40-106-RD-13 (6.0) / Saved on: 13 Jun 2018
10.
APPENDICES
Not applicable.


Boehringer Ingelheim
09 Sep 2019
BI Trial No.: 1371-0005
c26448055-04
Trial Protocol
Page 65 of 67
Proprietary confidential information © 2019 Boehringer Ingelheim International GmbH or one or more of its affiliated companies
001-MCS-40-106-RD-13 (6.0) / Saved on: 13 Jun 2018
11.
DESCRIPTION OF GLOBAL AMENDMENT(S)
11.1
GLOBAL AMENDMENT (REVISED PROTOCOL)
Revised Protocol, due to first submission to BfArM and ethic committee.
Date of amendment
(revision)
21 June 2019
EudraCT number
EU number
2019-000507-33
BI Trial number
1371-0005
BI Investigational Medicinal 
Product(s)
BI 894416
Title of protocol
Effect of rifampicin on the pharmacokinetics of a 
single oral dose of BI 894416 in healthy male 
subjects (an open-label, one-way crossover study)
CTP-version 2.0 is the first submission to IRB / IEC / Competent Authority
To be implemented only after approval of the IRB / IEC / Competent 
Authorities
To be implemented immediately in order to eliminate hazard – IRB / IEC / 
Competent Authority to be notified of change with request for approval
Can be implemented without IRB / IEC / Competent Authority approval as 
changes involve logistical or administrative aspects only
Section to be changed
All sections which address site specific 
requirements
Description of change
To be consistent with site specific requirements
Rationale for change
(1) Adaption to the local site requirements (
 
); (2) Change of CTL responsibilities


Boehringer Ingelheim
09 Sep 2019
BI Trial No.: 1371-0005
c26448055-04
Trial Protocol
Page 66 of 67
Proprietary confidential information © 2019 Boehringer Ingelheim International GmbH or one or more of its affiliated companies
001-MCS-40-106-RD-13 (6.0) / Saved on: 13 Jun 2018
11.2
GLOBAL AMENDMENT 2
Date of amendment
26 July 2019
EudraCT number
EU number
2019-000507-33
BI Trial number
1371-0005
BI Investigational Medicinal 
Product(s)
BI 894416
Title of protocol
Effect of rifampicin on the pharmacokinetics of a 
single oral dose of BI 894416 in healthy male 
subjects (an open-label, one-way crossover study)
To be implemented only after approval of the IRB / IEC / Competent 
Authorities
To be implemented immediately in order to eliminate hazard – IRB / IEC / 
Competent Authority to be notified of change with request for approval
Can be implemented without IRB / IEC / Competent Authority approval as 
changes involve logistical or administrative aspects only
Section to be changed
4.1.3
Method of assigning subjects to treatment 
groups
1.2.2
Rifampicin
Description of change
4.1.3
Justification of simultaneous dosing of all 
subjects on day 1
1.2.2
SmPC Update March 2019 (already 
submitted)
Rationale for change
4.1.3
Health authority / EC request
1.2.2
Came effected during CTP-Preparation


Boehringer Ingelheim
09 Sep 2019
BI Trial No.: 1371-0005
c26448055-04
Trial Protocol
Page 67 of 67
Proprietary confidential information © 2019 Boehringer Ingelheim International GmbH or one or more of its affiliated companies
001-MCS-40-106-RD-13 (6.0) / Saved on: 13 Jun 2018
11.3
GLOBAL AMENDMENT 3
Date of amendment
09 September 2019
EudraCT number
EU number
2019-000507-33
BI Trial number
1371-0005
BI Investigational Medicinal 
Product(s)
BI 894416
Title of protocol
Effect of rifampicin on the pharmacokinetics of a 
single oral dose of BI 894416 in healthy male 
subjects (an open-label, one-way crossover study)
To be implemented only after approval of the IRB / IEC / Competent 
Authorities
To be implemented immediately in order to eliminate hazard – IRB / IEC / 
Competent Authority to be notified of change with request for approval
Can be implemented without IRB / IEC / Competent Authority approval as 
changes involve logistical or administrative aspects only
Section to be changed
Title page
Flow chart
5.2.3 Safety laboratory parameters
5.3.2.1 Blood sampling for pharmacokinetic analysis
Description of change
Title page:
-
Department of TMCP was deleted
Flow chart: 
- Footnote 5 was corrected to 10
-
Cotinine test was added to screening 
examination in footnote 1
5.2.3 Safety laboratory parameters:
- Erythrocytes was corrected to haemoglobin
5.3.2.1 Blood sampling for pharmacokinetic 
analysis:
-
Correction of time and storage conditions for
rifampicin samples
Rationale for change
Title page: Due to internal restructure of 
organisation
Flow chart: Correction of inconsistence and typos
5.2.3: Correction of inconsistences due to 
quantification method
5.3.2.1: Correction due to new stability data of 
rifampicin in plasma


 
 
 
 
APPROVAL / SIGNATURE PAGE 
 
Document Number: 
 
Technical Version Number:
 
Document Name: 
 
 
 
                                                                                                                 
 
Title: 
 
 
 
 
                                                                                                                   
 
Signatures (obtained electronically) 
 
Meaning of Signature  
Signed by 
Date Signed 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
c26448055
4.0
clinical-trial-protocol-version-04
Effect of rifampicin on the pharmacokinetics of a single oral dose of BI 894416 in
healthy male subjects (an open-label, one-way crossover study)
Approval-Therapeutic Area 
09 Sep 2019 13:18 CEST
Author-Trial Statistician
09 Sep 2019 13:45 CEST
Author-Trial Clinical
Pharmacokineticist
09 Sep 2019 21:21 CEST
Approval-Team Member Medicine
13 Sep 2019 05:36 CEST
Approval-Clinical Trial Leader
13 Sep 2019 08:43 CEST
Verification-Paper Signature
Completion
16 Sep 2019 09:11 CEST


Boehringer Ingelheim 
Page 2 of 2
Document Number: 
 Technical Version Number:
 
 
 
(Continued) Signatures (obtained electronically) 
 
Meaning of Signature  
Signed by 
Date Signed 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
c26448055
4.0

SAP_001.pdf: 
TITLE PAGE
TRIAL STATISTICAL ANALYSIS PLAN
c30341373-01
BI Trial No.:
1371-0005
Title:
  Effect of rifampicin on the pharmacokinetics of a single oral dose
  of BI 894416 in healthy male subjects (an open-label, one-way
crossover study)
(including Protocol Amendments No.1-3 [c26448055-04])
Investigational
Product:
BI 894416
Responsible trial 
statisticians:
Phone:
Fax:
Date of statistical 
analysis plan:
19NOV2019 SIGNED
Version:
Final
Page 1 of 27
Proprietary confidential information
2019 Boehringer Ingelheim International GmbH or one or more of its affiliated companies. All rights reserved.
This document may not - in full or in part - be passed on, reproduced, published or otherwise used without prior written permission.


Boehringer Ingelheim
TSAP for BI Trial No: 1371-0005
Page 2 of 27
Proprietary confidential information © 2019 Boehringer Ingelheim International GmbH or one or more of its affiliated companies
1.
TABLE OF CONTENTS
TITLE PAGE ...........................................................................................................................1
1.
TABLE OF CONTENTS......................................................................................2
LIST OF TABLES...................................................................................................................4
2.
LIST OF ABBREVIATIONS ..............................................................................5
3.
INTRODUCTION.................................................................................................7
4.
CHANGES IN THE PLANNED ANALYSIS OF THE STUDY......................8
5.
ENDPOINTS .........................................................................................................9
5.1
PRIMARY ENDPOINTS.....................................................................................9
5.2
SECONDARY ENDPOINTS...............................................................................9
5.2.1
Key secondary endpoints......................................................................................9
5.2.2
Secondary endpoints.............................................................................................9
5.3.2
Safety endpoints ..................................................................................................10
6.
GENERAL ANALYSIS DEFINITIONS ..........................................................11
6.1
TREATMENTS...................................................................................................11
6.2
IMPORTANT PROTOCOL DEVIATIONS....................................................13
6.3
SUBJECT SETS ANALYSED...........................................................................13
6.5
POOLING OF CENTRES .................................................................................15
6.6
HANDLING OF MISSING DATA AND OUTLIERS....................................15
6.7
BASELINE, TIME WINDOWS AND CALCULATED VISITS ...................15
7.
PLANNED ANALYSIS......................................................................................17
7.1
DEMOGRAPHIC AND OTHER BASELINE CHARACTERISTICS.........18
7.2
CONCOMITANT DISEASES AND MEDICATION .....................................19
7.3
TREATMENT COMPLIANCE........................................................................19
7.4
PRIMARY ENDPOINTS...................................................................................19
7.4.1
Primary analysis of the primary endpoints......................................................19
 
7.5
SECONDARY ENDPOINTS.............................................................................21
7.5.1
Key secondary endpoints....................................................................................21
7.5.2
Secondary endpoints...........................................................................................21
7.6.2
Safety endpoints ..................................................................................................21
7.7
EXTENT OF EXPOSURE.................................................................................21
7.8
SAFETY ANALYSIS..........................................................................................22
7.8.1
Adverse Events ....................................................................................................22


Boehringer Ingelheim
TSAP for BI Trial No: 1371-0005
Page 3 of 27
Proprietary confidential information © 2019 Boehringer Ingelheim International GmbH or one or more of its affiliated companies
7.8.2
Laboratory data ..................................................................................................23
7.8.3
Vital signs.............................................................................................................24
7.8.4
ECG......................................................................................................................24
7.8.5
Others...................................................................................................................24
8.
REFERENCES....................................................................................................25
10.
HISTORY TABLE..............................................................................................27


Boehringer Ingelheim
TSAP for BI Trial No: 1371-0005
Page 4 of 27
Proprietary confidential information © 2019 Boehringer Ingelheim International GmbH or one or more of its affiliated companies
LIST OF TABLES
Table 6.1: 1
Treatments and labels used in the analysis.......................................................11
Table 6.1: 2
Flow chart of analysis phases for statistical analyses of AEs ..........................12
Table 6.3: 1
Subject sets analysed........................................................................................14
Table 10: 1
History table .....................................................................................................27


Boehringer Ingelheim
TSAP for BI Trial No: 1371-0005
Page 5 of 27
Proprietary confidential information © 2019 Boehringer Ingelheim International GmbH or one or more of its affiliated companies
2.
LIST OF ABBREVIATIONS
See Medicine Glossary:
website: glossary
Term
Definition / description
ALT
Alanine transaminase
AST
Aspartate transaminase
AUC0-tz
Area under the concentration-time curve of the analyte in plasma over the 
time interval from 0 to the last quantifiable data point
AUC0-∞
Area under the concentration-time curve of the analyte in plasma over the 
time interval from 0 extrapolated to infinity
BMI
Body mass index
BWU
Bioavailability/Bioequivalence, Within-Subject Design, uncontrolled
CI
Confidence interval
Cmax
Maximum measured concentration of the analyte in plasma
CV
Arithmetic coefficient of variation
DBLM
Database lock meeting
DILI
Drug induced liver injury
gCV
Geometric coefficient of variation
gMean
Geometric mean
LLT
Lower level term
IQRMP
Integrated Quality and Risk Management Plan
λz
Terminal rate constant of the analyte in plasma
Max
Maximum
MedDRA
Medical Dictionary for Regulatory Activities
Min
Minimum
N
Number non-missing observations
P10
10th percentile
P90
90th percentile
po
Orally
PKS
Pharmacokinetic parameter analysis set
Q1
1st quartile
Q3
3rd quartile


Boehringer Ingelheim
TSAP for BI Trial No: 1371-0005
Page 6 of 27
Proprietary confidential information © 2019 Boehringer Ingelheim International GmbH or one or more of its affiliated companies
Term
Definition / description
qd
Once daily
R 
Reference treatment
RAGe
Report Appendix Generator system
REP
Residual effect period
Rifa
Rifampicin
SD
Standard deviation
SOC
System organ class
T
Test treatment
TS
Treated set
ULN
Upper limit of normal
WHO-DD
World Health Organization Drug Dictionary
XPKISTAT
Library of SAS® Macros for PK analysis


Boehringer Ingelheim
TSAP for BI Trial No: 1371-0005
Page 7 of 27
Proprietary confidential information © 2019 Boehringer Ingelheim International GmbH or one or more of its affiliated companies
3.
INTRODUCTION
As per ICH E9 (1), the purpose of this document is to provide a more technical and detailed 
elaboration of the principal features of the analysis described in the protocol, and to include 
detailed procedures for executing the statistical analysis of the primary and secondary 
variables and other data.
This Trial statistical analysis plan (TSAP) assumes familiarity with the Clinical Trial Protocol 
(CTP). In particular, the TSAP is based on the planned analysis specification as written in 
CTP Section 7 “Statistical Methods and Determination of Sample Size”. Therefore, TSAP 
readers may consult the CTP for more background information on the study, e.g., on study 
objectives, study design and population, treatments, definition of measurements and 
variables, planning of sample size, randomisation.
Study data (including data entered in the RAVE EDC system and external data provided by 
suppliers) will be stored in a Clinical Data Repository (CDR).
Pharmacokinetic (PK) parameters will be calculated using Phoenix WinNonlinTM software 
(version 6.3 or higher, Certara USA Inc., Princeton, NJ, USA).
The statistical analyses will be performed within the validated working environment CARE, 
including SASTM (current Version 9.4, by SAS Institute Inc., Cary, NC, USA), and a number 
of SASTM-based tools (e.g., macros for the analyses of AE data or laboratory data; Report 
Appendix Generator system (RAGe) for compilation/formatting of the CTR appendices).


Boehringer Ingelheim
TSAP for BI Trial No: 1371-0005
Page 8 of 27
Proprietary confidential information © 2019 Boehringer Ingelheim International GmbH or one or more of its affiliated companies
4.
CHANGES IN THE PLANNED ANALYSIS OF THE STUDY
All analyses as planned in the CTP will be performed and are described in more detail in this 
TSAP. 


Boehringer Ingelheim
TSAP for BI Trial No: 1371-0005
Page 9 of 27
Proprietary confidential information © 2019 Boehringer Ingelheim International GmbH or one or more of its affiliated companies
5.
ENDPOINTS
The pharmacokinetic parameters listed in Section 2.1 of the CTP for drug BI 894416 will be 
calculated according to the BI Standard Operating Procedure (SOP) ‘Standards and processes 
for analyses performed within Clinical Pharmacokinetics/Pharmacodynamics’ [001-MCS-36-
472] (7).
5.1
PRIMARY ENDPOINTS
Section 2.1.2 of the CTP: 
The following pharmacokinetic parameters will be determined for BI 894416:

AUC0-∞(area under the concentration-time curve of the analyte in plasma over the 
time interval from 0 extrapolated to infinity)

Cmax (maximum measured concentration of the analyte in plasma)
5.2
SECONDARY ENDPOINTS
5.2.1
Key secondary endpoints
This section is not applicable as no key secondary endpoints have been defined in the CTP.
5.2.2
Secondary endpoints
Section 2.1.3 of the CTP:
The following pharmacokinetic parameter will be determined for BI 894416: 

AUC0-tz (area under the concentration-time curve of the analyte in plasma over the 
time interval from 0 to the last quantifiable data point)


Boehringer Ingelheim
TSAP for BI Trial No: 1371-0005
Page 10 of 27
Proprietary confidential information © 2019 Boehringer Ingelheim International GmbH or one or more of its affiliated companies
  
5.3.2
Safety endpoints
Section 2.2.2.2 of the CTP: Safety and tolerability of BI 894416 will be assessed based on:

Adverse events (including clinically relevant findings from the physical examination)

Safety laboratory tests

12-lead ECG

Vital signs (blood pressure, pulse rate)
 


Boehringer Ingelheim
TSAP for BI Trial No: 1371-0005
Page 11 of 27
Proprietary confidential information © 2019 Boehringer Ingelheim International GmbH or one or more of its affiliated companies
6.
GENERAL ANALYSIS DEFINITIONS
6.1
TREATMENTS
For basic study information on investigational products, assignment of treatment sequences 
and selection of doses, please see CTP, Sections 3 and 4.
The study will be performed as an open-label trial with two treatments (T and R) and one 
fixed sequence (R then T). 
In total, it was planned to assign 16 healthy male subjects.
For details of dosage and formulation see Table 6.1: 1 below:
Table 6.1: 1
Treatments and labels used in the analysis
Treatment
Short label
R
BI 894416, 2*25 mg tablet, po, qd
BI 
T
BI 894416, 2*25 mg tablet, qd + rifampicin, 600 mg tablet, qd
BI+Rifa
Section 1.2.3 of the CTP: The Residual Effect Period (REP, i.e., the period after the last 
dose with measurable drug levels and/or pharmacodynamic effects still likely to be present) 
of BI 894416 has not been defined yet. […] 
For the use of rifampicin in this trial, the REP is defined as 6 days.
The following separate study phases will be defined for the analyses of AEs:


Boehringer Ingelheim
TSAP for BI Trial No: 1371-0005
Page 12 of 27
Proprietary confidential information © 2019 Boehringer Ingelheim International GmbH or one or more of its affiliated companies
Table 6.1: 2
Flow chart of analysis phases for statistical analyses of AEs
Study 
analysis 
phase
Label
Start (inclusive)
End (exclusive)
Screening
Screening
Date of informed consent
Date/time of administration 
of BI 894416 in treatment 
period 1
On-treatment
BI
Date/time of administration 
of BI 894416 in treatment 
period 1
Date/time of first 
administration of rifampicin 
in treatment period 2
On-treatment
Rifa
Date/time of first 
administration of 
rifampicin in treatment 
period 2
Date/time of administration 
of BI 894416 in treatment 
period 2 
On-treatment
BI+Rifa
Date/time of administration 
of BI 894416 in treatment 
period 2
0:00h on the day after EoT 
visit
Section 7.3.4 of the CTP: Note that AEs occurring after the last per protocol contact but 
entered before final database lock will be reported to Pharmacovigilance only and will not be 
captured in the trial database.
Please note that all AEs reported between start of trial drug administration and the last per-
protocol contact will be considered on treatment.
The following AE displays will be provided in the report:
Section 15.3 and Appendix 16.1.13.1.8 (for ClinicalTrials.gov and EudraCT only) of the CTR 
displays:
In these displays, the on-treatment phase will be analysed (labelled with the name of the 
study treatment (short label)). Screening period will not be included in this analysis. 
The following totals will be provided in addition (Section 15.3 only):
a total over all on-treatment phases involving BI ("BI Total on treatment")
a total over all on-treatment phases included in this analysis ("Total on treatment")
In Section 15.4 and Appendix 16.2 (Listings) of the CTR displays screening will be included 
and no totals will be provided.
Tables of vital signs and laboratory values will present results by the above mentioned on 
treatment phases apart from “Rifa” treatment.


Boehringer Ingelheim
TSAP for BI Trial No: 1371-0005
Page 13 of 27
Proprietary confidential information © 2019 Boehringer Ingelheim International GmbH or one or more of its affiliated companies
For detailed information on the handling of the treatments refer to Technical TSAP ADS 
(analysis data set) plan and Data Reviewers guide. 
6.2
IMPORTANT PROTOCOL DEVIATIONS
Data discrepancies and deviations from the CTP will be identified for all treated subjects. 
Section 7.3 of the CTP: Important protocol deviation (IPD) categories will be suggested in 
the IQRMP, IPDs will be identified no later than in the Report Planning Meeting, and the 
IPD categories will be updated as needed.
Consistency check listings (for identification of deviations of time windows) and a list of 
protocol deviations (e.g. deviations in drug administration, in blood sampling times, etc.) will 
be provided to be discussed at the report planning meeting (RPM). At this meeting, all 
manual deviations identified at the sites by the CRAs and deviations too complex to program 
will be reviewed by the trial team to decide which are considered important. For definition of 
important protocol deviations (iPD), and for the process of identification of these, refer to the 
Boehringer Ingelheim (BI) SOP "Identify and Manage Important Protocol Deviations (iPD)" 
(2).
If any iPDs are identified, they are to be summarised into categories and will be captured in 
an accompanying Excel spreadsheet (3). Categories which are considered to be iPDs in this 
trial are defined in the integrated quality and risk management plan (IQRMP). If the data 
show other iPDs, the definition in the IQRMP will be supplemented accordingly by the time 
of the Report Planning Meeting.
The iPDs will be summarised and listed.
6.3
SUBJECT SETS ANALYSED
Section 7.3 of the CTP:

Treated set (TS): The treated set includes all subjects who were treated with at least one 
dose of study drug. The treated set will be used for safety analyses.

Pharmacokinetic parameter analysis set (PKS): This set includes all subjects in the 
treated set (TS) who provide at least one PK endpoint that was defined as primary or 
secondary and was not excluded due to a protocol deviation relevant to the evaluation of 
PK or due to PK non-evaluability (as specified in the following subsection 
‘Pharmacokinetics’). Thus, a subject will be included in the PKS, even if he contributes 
only one PK parameter value for one period to the statistical assessment. Descriptive 
and model based analyses of PK parameters will be based on the PKS.


Boehringer Ingelheim
TSAP for BI Trial No: 1371-0005
Page 14 of 27
Proprietary confidential information © 2019 Boehringer Ingelheim International GmbH or one or more of its affiliated companies
[…]
Pharmacokinetics
[…]
Plasma concentration data and parameters of a subject will be included in the statistical 
pharmacokinetic (PK) analyses if they are not flagged for exclusion due to a protocol 
deviation relevant to the evaluation of PK (to be decided no later than in the Report Planning 
Meeting) or due to PK non-evaluability (as revealed during data analysis, based on the 
criteria specified below). Exclusion of a subject’s data will be documented in the CTR.
Relevant protocol deviations may be

Incorrect trial medication taken, i.e. the subject received at least one dose of trial 
medication the subject was not assigned to

Incorrect dose of trial medication taken

Use of restricted medications
Plasma concentrations and/or parameters of a subject will be considered as non-evaluable, if 
for example

The subject experienced emesis that occurred at or before two times median tmax of the 
respective treatment (Median tmax is to be determined excluding the subjects 
experiencing emesis),

A pre-dose concentration of BI 894416 is >5% Cmax value of that subject in the 
respective treatment period

Missing samples/concentration data at important phases of PK disposition curve
The descriptive analysis of PK concentrations will be based on the ADS ADPC as described 
at the beginning of Section 7.
Table 6.3: 1
Subject sets analysed
Subject set
Class of endpoint
TS
PKS
Analyses of PK endpoints 
X
Safety parameters
X
Demographic/baseline parameters
X
Important protocol deviations
X
Disposition
X


Boehringer Ingelheim
TSAP for BI Trial No: 1371-0005
Page 15 of 27
Proprietary confidential information © 2019 Boehringer Ingelheim International GmbH or one or more of its affiliated companies
6.5
POOLING OF CENTRES
This section is not applicable, because the study was performed in only one centre.
6.6
HANDLING OF MISSING DATA AND OUTLIERS
Handling of missing data and outliers will be performed as described in the CTP, Section 7.5.
The only exceptions where imputation might be necessary for safety evaluation are AE dates. 
Missing or incomplete AE dates are imputed according to BI standards (see BI-KMED-BDS-
HTG-0035 (4)).
Missing data and outliers of PK data are handled according to BI standards (see 001-MCS-
36-472_RD-01) (5).
6.7
BASELINE, TIME WINDOWS AND CALCULATED VISITS
The baseline value is defined as the last measurement before administration of BI 894416 in 
each treatment period.
Section 6.1 of the CTP: Exact times of measurements outside the permitted time windows 
will be documented. The acceptable time windows for screening and the end of trial 
examination are provided in the CTP Flow Chart.
Study measurements and assessments scheduled to occur ‘before’ trial medication 
administration on Day 1 are to be performed and completed within a 3 h-period prior to the 
trial drug administration. 
The acceptable deviation from the scheduled time for vital signs, ECG, and laboratory tests 
will be ± 60 min..
[…]
For time point 34 h (planned time) after BI 894416 administration, a time window of ± 60 
min will be allowed for PK blood sampling. For time point 48 h (planned time) after BI 
894416 administration, a time window of ± 120 min will be allowed for PK blood sampling.
Adherence to time windows will be checked via the consistency check listings at the RPM.
Unscheduled measurements of laboratory data and vital signs data will be assumed to be 
repeat measurements of the most recent scheduled measurement (e.g. for follow-up or 


Boehringer Ingelheim
TSAP for BI Trial No: 1371-0005
Page 16 of 27
Proprietary confidential information © 2019 Boehringer Ingelheim International GmbH or one or more of its affiliated companies
confirmation of a particular value). Therefore, unscheduled measurements will be assigned to 
the planned time point of the previous scheduled measurement. 


Boehringer Ingelheim
TSAP for BI Trial No: 1371-0005
Page 17 of 27
Proprietary confidential information © 2019 Boehringer Ingelheim International GmbH or one or more of its affiliated companies
7.
PLANNED ANALYSIS
Safety analysis (refer to Section 7.8) will be performed by 
 and 
will be presented in Sections 15.1 to 15.4 of the CTR and in Appendix 16.2 and 16.1.13.1.
Inferential statistical analyses of PK endpoints (refer to Section 7.4 and Section 7.5.2) will
also be performed by 
and will be presented in Section 15.5 of 
the CTR and in Appendix 16.1.13.3.
Descriptive data analysis of PK endpoints and concentrations will be performed by the 
department Translational Medicine and Clinical Pharmacology (TMCP) at BI and will be 
presented in Section 15.6 of the CTR.
The format of the listings and tables will follow the BI standards (see BI-KMED-BDS-HTG-
0045 (6)) with the exception of those generated for PK-calculations (7).
The individual values of all subjects will be listed, sorted by sequence group, subject number, 
visit and actual treatment (if appropriate). 
The listings will be included in Appendix 16.2 of the CTR.
For end-of-text tables, the set of summary statistics for non-PK parameters is: 
N 
number non-missing observations 
Mean
arithmetic mean
SD
standard deviation 
Min
minimum 
Median
median 
Max
maximum
For analyte concentrations, the following descriptive statistics will additionally be calculated:
CV 
arithmetic coefficient of variation
gMean
geometric mean
gCV
geometric coefficient of variation
For PK parameters, the following descriptive statistics will additionally be calculated:
CV 
arithmetic coefficient of variation
gMean
geometric mean
gCV
geometric coefficient of variation
P10 
10th percentile
Q1 
1st quartile
Q3 
3rd quartile
P90 
90th percentile


Boehringer Ingelheim
TSAP for BI Trial No: 1371-0005
Page 18 of 27
Proprietary confidential information © 2019 Boehringer Ingelheim International GmbH or one or more of its affiliated companies
The data format for descriptive statistics of concentrations will be identical to the data format 
of the respective concentrations. The descriptive statistics of PK parameters will be 
calculated using the individual values with the number of decimal places as provided by the 
evaluation program. Then the individual values as well as the descriptive statistics will be 
reported with three significant digits in the CTR.
Tabulations of frequencies for categorical data will include all possible categories and will 
display the number of observations in a category, as well as the percentage (%). Percentages 
will be rounded to one decimal place and will be based on all subjects in the respective 
subject set whether they have non-missing values or not. The category 'missing' will be 
displayed only if there are actually missing values.
Units of variables should be given in the titles or column/row descriptors in square brackets 
(e.g. [mg]).
Exclusion of PK parameters
The ADS ADPP (PK parameters) contains column variables indicating inclusion/exclusion 
(APEXC) of a PK parameter and an analysis flag comment (APEXCO). All analyses based 
on the PKS will include parameters if they are not flagged for exclusion, that is APEXCO is 
equal to “Included”.
Exclusion of PK concentrations
The ADS ADPC (PK concentrations per time-point or per time-interval) contains column 
variables ACEXC and ACEXCO indicating inclusion/exclusion (ACEXC) of a concentration 
and an analysis flag comment (ACEXCO). Exclusion of a concentration depends on the 
analysis flag comment ACEXCO. For example, if ACEXCO is set to ‘ALL CALC’, the value 
will be excluded for all types of analyses based on concentrations. If ACEXCO is set to 
‘DESC STATS’ the value will be excluded from descriptive evaluations per planned time 
point/time interval. If ACEXCO contains the addition ‘TIME VIOLATION’ or ‘TIME 
DEVIATION’ the value can be used for further analyses based on actual times. If ACEXCO
is set to ‘HALF LIFE’, the value will be excluded from half-life calculation (and, as a 
consequence, any calculation that relies on λz) only; the value is included for all other 
analyses.
Further details are given in 001-MCS-36-472_RD-01 “Noncompartmental Pharmacokinetic / 
Pharmacodynamic Analyses of Clinical Studies” (5) and 001-MCS-36-472_RD-03 
“Description of Analytical Transfer Files and PK/PD Data Files” (11).
7.1
DEMOGRAPHIC AND OTHER BASELINE CHARACTERISTICS
Only descriptive statistics are planned for this section of the report, based on the TS.
The data will be summarised in total.


Boehringer Ingelheim
TSAP for BI Trial No: 1371-0005
Page 19 of 27
Proprietary confidential information © 2019 Boehringer Ingelheim International GmbH or one or more of its affiliated companies
7.2
CONCOMITANT DISEASES AND MEDICATION
Frequency tables are planned for this section of the report, based on the TS.
Concomitant diseases will be coded using the coding system of the Medical Dictionary for 
Drug Regulatory Activities (MedDRA). Medications will be coded using the World Health 
Organization Drug Dictionary (WHO-DD). The coding version number will be displayed as a 
footnote in the respective output.
The diagnoses and medications will be listed. Subjects without any concomitant diagnoses or 
concomitant therapies should be marked with a “No” in the respective column.
The relevance of the concomitant therapies to the evaluation of PK will be decided no later 
than at the RPM. 
7.3
TREATMENT COMPLIANCE
Section 4.3 of the CTP: Compliance will be assured by administration of all trial medication 
in the study centre under supervision of the investigating physician or a designee. The 
measured plasma concentrations of trial medication will provide additional confirmation of 
compliance.
It is not intended to list the compliance separately. Any deviations from complete intake will 
be addressed in the RPM (cf. TSAP Section 6.2) and described in the CTR.
7.4
PRIMARY ENDPOINTS
Relative bioavailability of BI 894416 in plasma is to be determined on the basis of the 
primary and secondary pharmacokinetic endpoints AUC0-∞, Cmax and AUC0-tz (see Section 
5.1 and Section 5.2). 
7.4.1
Primary analysis of the primary endpoints
Section 7.3.1 of the CTP: The statistical model used for the analysis of the primary 
endpoints will be a mixed effects model on the logarithmic scale. That is, the PK endpoints 
will be log-transformed (natural logarithm) prior to fitting the mixed effects model. This 
model will include effects accounting for the following sources of variation: subject and 
treatment. The effect ‘subjects’ will be considered as random, whereas treatment will be 
considered as fixed. The model is described by the following equation:


Boehringer Ingelheim
TSAP for BI Trial No: 1371-0005
Page 20 of 27
Proprietary confidential information © 2019 Boehringer Ingelheim International GmbH or one or more of its affiliated companies
ykm = µ + sm + τk + ekm, where
ykm = logarithm of response measured on subject m receiving treatment k,
µ = the overall mean,
sm = the effect associated with the mth subject, m = 1, 2, ..., n
τk = the kth treatment effect, k = 1, 2,
ekm = the random error associated with the mth subject who received treatment k.
where sm ~ N(0,
) i.i.d., ekm ~ N(0, 
 ) i.i.d. and sm, ekm are independent random variables. 
The indices ‘B’ and ‘W’ correspond to ‘between’ and ‘within’ variability, respectively.
Point estimates for the ratios of the geometric means (test/reference) for the primary 
endpoints (see Section 5.1) and their two-sided 90% confidence intervals (CIs) will be 
provided.
For each endpoint, the difference between the expected means for log(T)-log(R) will be 
estimated by the difference in the corresponding adjusted means (Least Squares Means). 
Additionally their two-sided 90% confidence intervals will be calculated based on the 
residual error from the mixed effects model and quantiles from the t-distribution. These 
quantities will then be back-transformed to the original scale to provide the point estimate 
and 90% CIs for each endpoint.
The implementation for this analysis will be accomplished by using the XPKISTAT macro, 
based on PKS, and option BWU (Bioavailability/Bioequivalence, within-subject design, and 
uncontrolled with respect to time).


Boehringer Ingelheim
TSAP for BI Trial No: 1371-0005
Page 21 of 27
Proprietary confidential information © 2019 Boehringer Ingelheim International GmbH or one or more of its affiliated companies
 
7.5
SECONDARY ENDPOINTS
7.5.1
Key secondary endpoints
This section is not applicable as no key secondary endpoint has been specified in the 
protocol.
7.5.2
Secondary endpoints
The secondary PK parameter AUC0-tz will be assessed using the same methods as described 
for the primary endpoints.
7.6.2
Safety endpoints
Refer to TSAP Section 7.8 for a description of the analysis of safety and tolerability of 
BI 894416.
7.7
EXTENT OF EXPOSURE
Descriptive statistics are planned for this section of the report based on the TS. The date and 
time of drug administration will be listed for each subject.


Boehringer Ingelheim
TSAP for BI Trial No: 1371-0005
Page 22 of 27
Proprietary confidential information © 2019 Boehringer Ingelheim International GmbH or one or more of its affiliated companies
7.8
SAFETY ANALYSIS
All safety analyses will be performed on the TS. 
The safety data for treated subjects who failed to complete the study (dropouts or 
withdrawals) will be reported as far as their data are available. All withdrawals will be 
documented and the reason for withdrawal recorded.
7.8.1
Adverse Events
AEs will be coded with the most recent version of MedDRA.
The analyses of AEs will be descriptive in nature and will be based on BI standards as 
presented in “Analysis and Presentation of Adverse Event Data from Clinical Trials –
Display Template” [BI-KMED-BDS-HTG-0041] (8). All analyses of AEs will be based on 
the number of subjects with AEs and not on the number of AEs.
For analysis multiple AE occurrence data on the eCRF will be collapsed into one AE 
provided that all of the following applies:

All AE attributes are identical (lower level term (LLT), intensity, action taken, 
therapy required, seriousness, reason for seriousness, relationship, outcome, AE of 
special interest (AESI))

The occurrences were time-overlapping or time-adjacent (time-adjacency of 
two occurrences is given if the second occurrence started within one hour after end of 
the first occurrence).
The analysis of AEs will be based on the concept of treatment emergent AEs. That means 
that all AEs will be assigned to screening or on-treatment phases as defined in Section 6.1.
AEs will be analysed based on actual treatments, as defined in Table 6.1: 1
Section 5.2.6.1.4 of the CTP: The following are considered as AESIs:

Hepatic injury
A hepatic injury is defined by the following alterations of hepatic laboratory 
parameters:
o
An elevation of AST (aspartate transaminase) and/or ALT (alanine 
transaminase) ≥3-fold ULN combined with an elevation of total bilirubin 
≥2-fold ULN measured in the same blood sample, or
o
Aminotransferase (ALT, and/or AST) elevations ≥10 fold ULN
These lab findings constitute a hepatic injury alert and the subjects showing these lab 
abnormalities need to be followed up according to the 'DILI checklist’ provided in the 
ISF or in eDC, as applicable. In case of clinical symptoms of hepatic injury (icterus, 
unexplained encephalopathy, unexplained coagulopathy, right upper quadrant 


Boehringer Ingelheim
TSAP for BI Trial No: 1371-0005
Page 23 of 27
Proprietary confidential information © 2019 Boehringer Ingelheim International GmbH or one or more of its affiliated companies
abdominal pain, etc.) without lab results (ALT, AST, total bilirubin) available, the 
Investigator should make sure that these parameters are analysed, if necessary in an 
unscheduled blood test. Should the results meet the criteria of hepatic injury alert, the 
procedures described in the DILI checklist should be followed.
According to ICH E3 (9), AEs classified as ‘other significant’ need to be reported and will 
include those non-serious and non-significant AE with
(i) ‘action taken = discontinuation’ or ‘action taken = reduced’, or
(ii) marked haematological and other lab abnormalities or lead to significant concomitant
therapy as identified by the Clinical Monitor/Investigator at a RPM.
An overall summary of AEs (including AESIs and other significant AEs) will be presented.
The frequency of subjects with AEs will be summarised by treatment, primary system organ 
class (SOC) and preferred term (PT). Separate tables will be provided for subjects with other 
significant AEs according to ICH E3 (9), for subjects with serious AEs, for subjects with 
drug-related AEs, for subjects with drug related serious adverse events and for subjects with 
AESIs. In addition, the frequency of subjects with AEs will be summarised by treatment, 
worst intensity, primary system organ class (SOC) and preferred term (PT).
The SOCs and PTs will be sorted by frequency (within SOC). The MedDRA version number 
will be displayed as a footnote in the respective output.
In addition, frequencies of subjects with non-serious AEs that had an incidence of > 5% for at 
least one treatment will be summarised by treatment, primary SOC and PT.
For disclosure of adverse events on EudraCT, additional information not included in a 
standard AE analysis will be performed. The following three entries will be created:

Adverse Events per arm for disclosure on EudraCT

Non-serious Adverse Events for disclosure on EudraCT

Serious Adverse Events for disclosure on EudraCT
7.8.2
Laboratory data
The analyses of laboratory data will be descriptive in nature and will be based on 
BI standards [BI-KMED-BDS-HTG-0042] (10). 
Laboratory data will be analysed qualitatively via comparison of laboratory data to their 
reference ranges. Values outside the reference range as well as values defined as possibly
clinically significant will be flagged in the data listings.
Clinically relevant findings in laboratory data will be reported as baseline conditions (at 
screening) or as AEs (during the trial) if judged clinically relevant by the investigator, and 
will be analysed as such.


Boehringer Ingelheim
TSAP for BI Trial No: 1371-0005
Page 24 of 27
Proprietary confidential information © 2019 Boehringer Ingelheim International GmbH or one or more of its affiliated companies
It is the investigator's responsibility to decide whether a lab value is clinically significantly 
abnormal or not (at the RPM/DBLM at the latest). 
Descriptive statistics of laboratory data including change from baseline will be calculated by 
planned time point based on the worst value of the subject at that planned time point (or 
assigned to that planned time point).
7.8.3
Vital signs
For vital signs (blood pressure and pulse rate), descriptive statistics including change from 
baseline will be calculated by planned time point based on the last value of the subject at that 
planned time point (or assigned to that planned time point). In the listing the difference from 
baseline will also be displayed.
Clinically relevant findings in vital signs will be reported as AEs.
7.8.4
ECG
ECG recordings will be checked by the investigator for pathological results. Clinically 
relevant abnormal findings for ECG will be listed under 'Relevant Medical History / Baseline 
Conditions' (if they pre-exist prior to trial inclusion) or will be reported as AEs (if they 
occurred during treatment), and will be analysed as such.
7.8.5
Others
This section is not applicable as no other safety endpoint has been specified in the protocol.


Boehringer Ingelheim
TSAP for BI Trial No: 1371-0005
Page 25 of 27
Proprietary confidential information © 2019 Boehringer Ingelheim International GmbH or one or more of its affiliated companies
8.
REFERENCES
1.
CPMP/ICH/363/96: "Statistical Principles for Clinical Trials", ICH Guideline Topic E9, 
Note For Guidance on Statistical Principles for Clinical Trials, current version.
2.
001-MCS-40-413: "Identify and Manage Important Protocol Deviations (iPD) ", current 
version, IDEA for CON.
3.
BI-KMED-COPS-TMP-0001: "iPD log", current version; KMED.
4.
BI-KMED-BDS-HTG-0035: “Handling of Missing and Incomplete AE Dates”, current 
version; KMED.
5.
001-MCS-36-472_RD-01: “Noncompartmental Pharmacokinetic/Pharmacodynamic 
Analyses of Clinical Studies”, current version; IDEA for CON.
6.
BI-KMED-BDS-HTG-0045: “Standards for Reporting of Clinical Trials and Project
Summaries”, current version; KMED.
7.
001-MCS-36-472: "Standards and processes for analyses performed within Clinical 
Pharmacokinetics/Pharmacodynamics", current version; IDEA for CON.
8.
BI-KMED-BDS-HTG-0041: “Analysis and Presentation of Adverse Event Data from 
Clinical Trials – Display Template”, current version; KMED.
9.
CPMP/ICH/137/95: “Structure and Content of Clinical Study Reports”, ICH Guideline 
Topic E3; Note For Guidance on Structure and Content of Clinical Study Reports, 
current version.
10. BI-KMED-BDS-HTG-0042: “Handling, Display and Analysis of Laboratory Data”, 
current version; KMED.
11. 001-MCS-36-472_RD-03: “Description of Analytical Transfer Files and PK/PD Data 
Files”, current version; IDEA for CON.


Boehringer Ingelheim
TSAP for BI Trial No: 1371-0005
Page 26 of 27
Proprietary confidential information © 2019 Boehringer Ingelheim International GmbH or one or more of its affiliated companies


Boehringer Ingelheim
TSAP for BI Trial No: 1371-0005
Page 27 of 27
Proprietary confidential information © 2019 Boehringer Ingelheim International GmbH or one or more of its affiliated companies
10.
HISTORY TABLE
Table 10: 1
History table
Version
Date
(DD-MMM-YY)
Author
Sections 
changed
Brief description of change
Final
19-NOV-2019
None
This is the final TSAP.